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Abstract 45 
 46 
Objective 47 
Glucocorticoids (GCs) are widely prescribed medications that are well recognized to cause adverse 48 
metabolic effects including hyperphagia, obesity, and hyperglycemia. These effects have been 49 
recapitulated in a murine model of GC excess, and we hypothesize that they are mediated, in part, 50 
through central mechanisms. This study aimed to identify genes in the hypothalamic arcuate nucleus 51 
(ARC) that are altered with GC treatment and evaluate their contribution to GC-induced metabolic 52 
abnormalities. 53 
 54 
Methods 55 
Corticosterone (Cort; 75μg/ml) was administered in the drinking water to male C57Bl/6J mice for 2 56 
days or 4 weeks. Phenotypic analysis of each group was undertaken and central and peripheral 57 
tissues were collected for biochemical and mRNA analyses. Arcuate nuclei were isolated by laser 58 
capture microdissection and tissue analyzed by RNA-seq.  59 
 60 
Results 61 
RNA-seq analysis of ARC tissue from 4 week Cort treated mice revealed 21 upregulated and 22 62 
downregulated genes at a time when mice had increased food intake, expansion of adipose tissue 63 
mass, and insulin resistance. In comparison, after 2 days Cort treatment, when the main phenotypic 64 
change was increased food intake, RNA-seq identified 30 upregulated and 16 downregulated genes. 65 
Within the genes altered at 2 days were a range of novel genes but also those known to be regulated 66 
by GCs, including Fkbp5, Mt2, Fam107a, as well as some involved in the control of energy balance, 67 
such as Agrp, Sepp1, Dio2, and Nmb. Of the candidate genes identified by RNA-seq, type-II 68 
iodothyronine deiodinase (Dio2) was chosen for further investigation as it was increased (2-fold) 69 
with Cort, and has been implicated in the control of energy balance via the modulation of 70 
hypothalamic thyroid hormone availability. Targeted knockdown of Dio2 in the MBH using AAV-71 
mediated CRISPR-Cas9 produced a mild attenuation in GC-induced brown adipose tissue weight gain, 72 
as well as a 56% reduction in the GC-induced increase in Agrp. However, this conferred no 73 
protection from GC-induced hyperphagia, obesity, or hyperglycemia. 74 
 75 
Conclusion 76 
This study identified a comprehensive set of genes altered by GCs in the ARC and enabled the 77 
selection of key candidate genes. Targeted knockdown of hypothalamic Dio2 revealed that it did not 78 
mediate the chronic GC effects on hyperphagia and hyperglycemia. 79 
 80 
Keywords Glucocorticoid, Arcuate Nucleus, RNA-Seq, Dio2, CRISPR-Cas9 81 
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1. Introduction 90 
Glucocorticoids (GCs) are extensively prescribed medicines due to their potent immunosuppressive 91 
and anti-inflammatory properties. It has been estimated that, at any one time, up to 1% of the adult 92 
population in the UK and US may be receiving oral GC therapy [1–4], with nearly one quarter of 93 
patients requiring GCs for longer than 6 months [2]. Prolonged high-dose GC use is associated with a 94 
range of metabolic side effects, including hyperphagia, obesity, and abnormal glucose homeostasis 95 
[4–6]. Despite their regular occurrence, the mechanisms driving these adverse metabolic effects 96 
remain unclear.  97 
 98 
Although GCs have a variety of well-known peripheral effects, recent evidence suggests that their 99 
adverse metabolic outcomes may be mediated, at least in part, through central mechanisms. Indeed, 100 
intracerebroventricular but not peripheral infusion of the synthetic glucocorticoid receptor (GR) 101 
agonist dexamethasone (DEX) caused an increase in food intake, body weight gain, and induced 102 
insulin resistance [7–9]. A potential region involved in driving these GC-induced side effects is the 103 
hypothalamic arcuate nucleus (ARC), a region with high levels of GR expression [10] that is critical for 104 
the regulation of feeding and metabolism [11–14]. The ARC contains two functionally opposed 105 
neuronal populations, expressing agouti-related peptide (AgRP), and pro-opiomelanocortin (POMC) 106 
[11], regarded as the primary energy regulatory neurons. Both neurons and glia of the ARC are 107 
responsive to peripheral hormones, including leptin, insulin, and ghrelin, which elicit many of their 108 
effects via this nucleus [15–17]. However, despite their potent orexigenic and obesogenic effects, 109 
the role of GCs in this nucleus remains relatively unexplored.  110 
 111 
To be able to more fully investigate the central effects of chronic GCs, a model system that 112 
recapitulates the broad range of metabolic sequelae observed in humans with GC excess is required.  113 
Accordingly, a model of GC-induced metabolic syndrome has been presented by Karatsoreos et al. 114 
(2010) in which mice are delivered Cort in the drinking water, thereby limiting the stress associated 115 
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with daily injections or surgical Cort pellet implantation. In previous studies, we have characterized a 116 
similar mouse model of GC excess using Cort delivery in the drinking water [19,20] and shown that 117 
this leads to elevated hypothalamic Cort [19]. Using this model, we have characterized the 118 
development of metabolic changes over time and reported that chronic Cort delivery successfully 119 
induces hyperphagia and obesity, as well as hyperglycemia, hyperinsulinemia, and insulin resistance 120 
[19,20]. We also found a consistent increase in hypothalamic Agrp across multiple time points, 121 
leading us to investigate whether AgRP mediated the GC-induced metabolic abnormalities. However, 122 
Cort-treated Agrp null mice still developed obesity, hyperinsulinemia, and hyperglycemia [20], 123 
suggesting the involvement of other mechanisms.  124 
 125 
In the current study, we used a global transcriptomic approach to investigate the effects of GCs in 126 
the hypothalamus. To impartially identify genes that are differentially expressed in the ARC with 127 
long- (4 weeks) and short-term (2 days) Cort treatment, we used our model of GC excess in 128 
combination with laser capture microdissection and RNA-seq. This revealed a variety of genes 129 
involved in energy regulation, of which type-II iodothyronine deiodinase (Dio2) was selected as the 130 
most promising candidate for further study. To determine the contribution of elevated Dio2 in GC-131 
induced hyperphagia and obesity, an AAV-mediated CRISPR-Cas9 approach was employed to knock 132 
down Dio2 in the mediobasal hypothalamus (MBH), before mice were challenged with Cort for 4 133 
weeks. Disruption of Dio2 attenuated the GC-induced increase in Agrp; however, knockdown 134 
conferred no protection from the observed hyperphagia or weight gain.  135 
 136 
137 
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2. Materials and Methods 138 
2.1.    Animal husbandry 139 
Male C57Bl/6J mice (10 week old; Charles River) were singly housed under 12 hr light/dark cycle 140 
(lights on 7am, zeitgeber time [ZT] 0, lights off 7pm, ZT12) at an ambient temperature of 23±1˚C with 141 
a relative humidity of approximately 40% in specific pathogen-free housing with wood chip bedding 142 
and environmental enrichment. Food (RM1-P chow; SDS) and water were available ad libitum 143 
throughout experiments. All experiments were performed in accordance with the UK Animals 144 
(Scientific Procedures) Act of 1986, using procedures approved by The University of Manchester 145 
Ethical Review Panel. 146 
 147 
2.2.    In vivo study design and methodology 148 
For all studies mice were singly housed upon arrival and acclimatized for 1 week before undergoing 149 
1-2 weeks of baseline measurements prior to study start. Food intake, water intake, and body 150 
weight were monitored either daily (2 day study) or twice weekly (4 week studies) throughout 151 
baseline and study periods. All mice were culled by rising CO2 (at 10am). Tissues were snap frozen on 152 
dry ice and stored at -80°C until use. See below for in vivo treatments and methodology specific to 153 
each study group. 154 
 155 
2.2.1.   Mice used for RNA-seq of arcuate nuclei. Mice were assigned into two treatment groups so 156 
that each group contained mice with equivalent baseline body weight. Mice were administered 157 
either corticosterone (Cort; Sigma-Aldrich, 75µg/ml dissolved in 1% ethanol) or vehicle (1% ethanol) 158 
in the drinking water for a period of either 2 days or 4 weeks. Mice in the 2 day group were 159 
immediately culled following treatment. At the end of the 4 week treatment period mice underwent 160 
16 hr fast (6pm – 10am) followed by sampling for glucose and insulin. Mice were culled after being 161 
refed for 24 hr and brains were taken for RNA-seq (referred to as 4 week samples henceforth).  162 
 163 
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 164 
2.2.2.   Mice used for Dio2 knockdown study. Mice were assigned into two groups with equivalent 165 
final baseline body weight and received intracranial injections of either AAV-gRNA or AAV-null viral 166 
particles (described below). Post-surgery, mice were monitored for 2-3 weeks to allow for recovery 167 
and expression of viral constructs. Mice then underwent a baseline period, and each group was 168 
again split into two cohorts with equivalent body weight to receive either Cort (75µg/ml dissolved in 169 
1% ethanol) or vehicle (1% ethanol) in the drinking water for a period of 4 weeks. This resulted in 4 170 
treatment groups: AAV-null vehicle treated (Ctrl-Veh); AAV-null Cort treated (Ctrl-Cort); AAV-gRNA 171 
vehicle treated (KO-Veh); AAV-gRNA Cort treated (KO-Cort). A separate cohort of mice were culled 2 172 
weeks post-injection and used to verify viral targeting by immunohistochemistry, and successful in 173 
vivo gene editing by droplet digital PCR (ddPCR).  174 
 175 
2.2.3.   AAV vector synthesis. AAV2/8 vectors containing SaCas9 constructs were generated by UNC 176 
Vector Core. Prior to packaging, constructs containing gRNA1 and gRNA2 were mixed 1:1, thus 177 
producing a heterogeneous AAV population in which 50% of the viral particles contain gRNA1 and 178 
50% contain gRNA2 (collectively referred to as AAV-gRNA henceforth; 1.2 x 1013 vg/ml). A construct 179 
containing SaCas9 with no gRNA was also packaged for use as a control (AAV-null; 1.7 x 1013 vg/ml). 180 
 181 
2.2.4.   Stereotactic surgery. Male C57Bl/6J mice at 12 weeks of age were injected with AAV viral 182 
particles while maintained under isoflurane anesthesia. Bilateral injections (100 nl/injection) were 183 
directed towards the mediobasal hypothalamus at the coordinates: AP, -1.35 mm, L ±0.3 mm, DV, -184 
6.0 mm (from bregma). Injections were delivered using a Hamilton syringe and needle (33G). 185 
 186 
2.3.    Biochemical measurements 187 
Blood samples were taken by tail-prick microsampling. Blood was either used fresh, or plasma was 188 
stored at -80˚C until use. Plasma corticosterone concentrations were quantified using an ELISA 189 
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(Cayman Chemical) according to the manufacturer’s instructions. All samples for the measurement 190 
of corticosterone were taken within 1 minute of cage disturbance. Blood glucose was measured in 191 
fresh blood using a glucometer (Accu-Chek, Roche). Circulating insulin was quantified in fresh blood 192 
(4 week) or plasma (2 day) using an Ultrasensitive Mouse Insulin ELISA (Crystal Chem) according to 193 
the manufacturer’s instructions. HOMA-IR was calculated using the formula: [glucose (mmol/l) x 194 
insulin (mU/l)]/22.5.  195 
 196 
2.4.    Laser capture microdissection  197 
Brains were collected from mice after 2 days or 4 weeks of Cort treatment. Brains were snap frozen 198 
and stored at -80˚C before cryosectioning. Consecutive coronal sections (2 day, 30μm; 4 week, 12 199 
μm) encompassing the whole ARC (-1.46 to -2.7 mm caudal to bregma [21]) were mounted onto 200 
RNAse-free membrane (2 day; MMI) or Superfrost™ Plus slides (4 week; Thermo Scientific). Frozen 201 
sections were fixed in 95% ethanol and rehydrated in 75% and 50% ethanol. Slides were stained with 202 
cresyl violet to reveal the hypothalamic cytoarchitecture (Ambion), then dehydrated in a graded 203 
ethanol series and left to air dry prior to dissection. The entire ARC was dissected from 4 week 204 
samples using the PALM Microbeam Laser Capture Microdissection System (Zeiss), and from 2 day 205 
samples using an MMI CellCut Laser Microdissection System mounted onto an IX83 inverted 206 
microscope (Olympus). RNA was extracted using an RNeasy Micro Plus Kit (Qiagen) according to 207 
manufacturer’s instructions and analyzed for RNA integrity on an Agilent 2100 Bioanalyzer using an 208 
RNA 6000 Pico Kit. All RNA that was subsequently amplified had RNA integrity (RIN) scores >6.5. 209 
 210 
2.5.     Library preparation, RNA-seq, and bioinformatics  211 
2ng of RNA was converted to cDNA using the Ovation RNA-seq System V2 (NuGEN). The resultant 212 
cDNA was then fragmented to an average size of ~200bp using Bioruptor Pico (Diagenode) before 213 
end repair and adaptor ligation was performed using the Ovation Rapid DR Multiplex System 9-16 214 
(NuGEN) to allow multiplex sequencing. Prepared libraries were quantified using KAPA Library 215 
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Quantification Kit (KAPA Biosystems) and submitted to CRUK Cambridge institute for sequencing in a 216 
single lane on a HiSeq4000 (Illumina; 2 day samples) or HiSeq2500 (Illumina; 4 week samples). 217 
Single-end reads (50bp) were obtained with average reads of 24.67 million and 14.47 million in 2 day 218 
and 4 week samples, respectively. Read count for each sample is shown in Supplemental Table 1.  219 
 220 
Reads were mapped to the Mus Musculus GRCm38 reference assembly (Ensembl) in RStudio using 221 
Rsubread [22] before reads to specific genes were quantified using featureCounts [23]. The average 222 
mapping rate was 74.72% for 2 day Cort treated samples and 87.35% for 4 week treated samples. 223 
Expression levels are represented as counts per million (CPM) mapped reads. Prior to differential 224 
expression analysis, global transcriptomic profiles were used to construct principal component 225 
analysis (PCA) plots to visualize the distances between samples and identify outliers (Supplemental 226 
Fig. 1). In each dataset, 2 vehicle and 1 Cort treated sample were identified as outliers and excluded 227 
from future analysis, which resulted in n=3 vehicle and n=4 Cort replicates for each dataset. 228 
Differential expression analysis was then performed using the DESeq2 package [24]. All genes 229 
discussed had a Benjamini-Hochberg adjusted P value <0.1 (Padj<0.1). RNA-seq datasets were 230 
deposited in the NCBI Gene Expression Omnibus Database (accession number GSE128148). Gene 231 
ontology enrichment analysis was performed using the PANTHER online classification tool 232 
(http://pantherdb.org/; [22]). For each dataset, upregulated and downregulated genes (P<0.05, Padj 233 
present) were separated and used for an independent analysis, for a total of 4 analyses. Statistical 234 
overrepresentation was performed on default settings using a Fisher's Exact test with FDR multiple 235 
test correction. Upstream Regulator Analysis was performed independently on genes altered in 2 236 
day and 4 week datasets (P<0.05, Padj present) using Ingenuity Pathway Analysis (IPA, QIAGEN 237 
Redwood City, www.qiagen.com/ingenuity). 238 
 239 
2.6.    Quantification of mRNA by qRT-PCR 240 
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RNA-seq expression changes were confirmed in 2 day treated replicate samples by qRT-PCR. Briefly, 241 
cDNA was freshly prepared from total RNA (n=2 vehicle and n=2 Cort) used to generate the RNA-seq 242 
data as well as from 5 additional 2 day Cort, and 5 additional vehicle treated ARC samples. Gene 243 
expression was determined using a 48.48 Dynamic Array microfluidic chip on the BioMark HD Real-244 
Time PCR System (Fluidigm). 42 differentially expressed (P<0.01) genes and 5 normalization genes 245 
were quantified. Relative fold-change in expression was determined by the delta-delta Ct method (2-246 
ΔΔCt) [23] using Gapdh as the normalizer and the vehicle group as the calibrator. The list of SYBR qRT-247 
PCR primers used is shown in Supplemental Table 2.  248 
 249 
2.7.    In situ hybridization 250 
In situ hybridization was carried out as previously described [19]. Briefly, frozen brains were 251 
coronally cryosectioned (12μm). Representative sections through the whole hypothalamus were 252 
analyzed to ensure inclusion of all anatomical levels.  253 
 254 
In situ riboprobes targeting Dio2 (NM_010050.1, 948 base pairs between 666-1614), and Hr 255 
(NM_021877.2, 840 base pairs between 1933-2773) were generated by gene synthesis and 256 
subcloning of the sequence (GeneArt) into pGEM-5ZF(+) (Promega) and pGEM-T Easy Vector System 257 
(Promega), respectively. The resultant plasmid constructs were linearized using appropriate 258 
restriction enzymes to generate templates for sense and antisense riboprobe synthesis using the T7 259 
polymerase in vitro transcription system (Promega) in the presence of 33P-uridine triphosphate 260 
(PerkinElmer). Probes were hybridized overnight, and hybridization was visualized by 261 
autoradiography (Kodak Bio-Max MR film, Kodak). Films were imaged using a CoolSNAP-Pro camera 262 
(Photometrics). Signal was quantified by densitometry analysis of all autoradiograph images positive 263 
for the gene of interest.  264 
 265 
2.8.    Design of Dio2 targeted guide RNAs 266 
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To generate knockdown of Dio2 we used Clustered Regularly Interspaced Short Palindromic Repeats 267 
(CRISPR)-Cas9 technology, and designed two guide RNAs (gRNAs) in exon 1 of the Dio2 gene. The 268 
gRNA for S. aureus Cas9 (SaCas9) were selected using http://crispor.tefor.net/ [24]. The two gRNAs 269 
selected (PAM site in italics) were g1 = CCACGTGCTTGAGCAGAATGA-CCGAGT and g2 = 270 
GCCGCTCCAAGTCCACTCGCG-GAGAGT and were predicted to have no potential off targets with 271 
mismatches of 0, 1, 2, or 3 elsewhere in the genome, indicating their high specificity. 272 
 273 
Oligos for the gRNAs were ligated and cloned into an all-in-one vector system (Addgene, Plasmid ID 274 
61591 [25]) containing a CMV-driven SaCas9 cassette, with the gRNA expressed adjacent to a 275 
scaffold sequence and under the control of a ubiquitous polymerase III (U6) promoter (SaCas9-gRNA 276 
plasmid). A triple HA-epitope tag conjugated to the SaCas9 enzyme was also included for 277 
identification of SaCas9 expressing cells.  278 
 279 
2.9.    Cell culture, transfection, and genomic DNA isolation  280 
Mouse embryonic fibroblast cells (NIH-3T3) were cultured in medium (DMEM, Gibco) containing 281 
10% fetal bovine serum (Biowest). To screen for gRNA efficiency, NIH-3T3 cells were co-transfected 282 
with the SaCas9-gRNA plasmid and a plasmid containing CMV-driven GFP using FuGENE HD 283 
(Promega). 48 hr after transfection, GFP-positive cells were collected by fluorescence-activated cell 284 
sorting (FACS; CyAn ADP High-Speed Analyzer, Beckman Coulter). DNA was immediately extracted 285 
from GFP-positive cells using the PureLink Genomic DNA Mini Kit (Invitrogen) and stored at -20˚C 286 
until use. 287 
 288 
2.10. Droplet digital polymerase chain reaction 289 
For validation of in vivo editing, ARC tissue was dissected from injected animals using laser capture 290 
microdissection as described above (2 day samples). Hypothalamic regions to be excised were 291 
determined by the pattern of SaCas9 expression, visualized by anti-HA immunohistochemistry on 292 
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adjacent slices (see below). DNA was immediately extracted using the ARCTURUS® PicoPure® DNA 293 
Extraction Kit (Applied Biosystems) and stored at -20˚C until use. 294 
 295 
Quantification of gene editing frequency (GEF) was performed on in vitro (transfected 3T3 cells) and 296 
in vivo (laser-captured tissue) samples as described previously [26]. Prior to ddPCR, in vivo DNA 297 
samples underwent PCR pre-amplification (New England Biolabs) of the Dio2 gene using the forward, 298 
5’-ACCGAGGAGGCAGAGAAGAT-3’, and reverse, 5’-GTGAGGTCACAGCCATCGTCA-3’, primers, which 299 
flank the gRNA target sites. Reaction products were purified using a QIAquick PCR Purification Kit 300 
(Qiagen). Each ddPCR reaction mix contained: ddPCR Supermix for Probes (no dUTP; 1x Bio-Rad), 301 
forward primer, reverse primer, reference probe (FAM), InDel+ probe (HEX), and gDNA template. 302 
Droplets were generated using a QX200 droplet reader (Bio-Rad) and thermal cycling was 303 
performed. Droplets were quantified using a QX200 droplet reader (Bio-Rad). DNA from SaCas9-304 
Control treated cells was used as a negative control. ll ddPCR analysis was performed with 305 
Quantasoft software (Bio-Rad) using 2D amplitude dot plots. GEF was calculated using the following 306 
formula: GEF (%) = (1-(ratio of cleaved fraction)) x 100.  307 
 308 
All ddPCR probes were designed using Primer-BLAST (NCBI) software according to previously 309 
established guidelines [28]. All probes included a fluorophore (FAM or HEX) at the 5’ end and a black 310 
hole quencher (BHQ1) at the 3’ end. Primers and probes were as follows: forward primer, 5’-311 
CTGATCACCCTGCAGATCCT-3’; reverse primer, 5’- CCTGTTTGTAGGCATCTAGGAG -3’; reference 312 
probe, 5’-TTCTCCAACTGCCTCTTCCTGGC-3’, InDel+ probe 1, 5’-GGTCATTCTGCTCAAGCACGT-3’, 313 
InDel+ probe 2, 3’-ACTCTCCGCGAGTGGACTTGGA-5’. 314 
 315 
2.11.     Anti-HA Immunohistochemistry 316 
Brains were coronally cryosectioned (14µm). Sections were taken throughout the whole 317 
hypothalamus (-0.46 to -2.80 mm caudal to bregma [21]). Sections were fixed in 4% PFA, 318 
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permeabilized in 0.25% Triton-X, and blocked with 10% SeaBlock (Calbiochem). For anti-HA 319 
immunohistochemistry, sections were incubated with rabbit polyclonal anti-HA (ab9110, Abcam) 320 
primary antibody (1:1000) followed by donkey anti-rabbit Alexafluor 488 (1:150) secondary 321 
antibody. Endogenous tissue autofluorescence was dampened by incubation with 0.15% Sudan 322 
Black. Slides were mounted with Prolong Gold Antifade Mountant with DAPI (Thermo Scientific). 323 
Images were collected on a M205 FA Upright Stereomicroscope (Leica) and captured using a DFC 324 
565FX (Leica) camera through LAS AF v3.1.0.8587 software (Leica). Images were processed and 325 
analyzed using Image J.  326 
 327 
2.12.    Micropunch biopsies and quantification of mRNA by real-time quantitative PCR 328 
Micropunch biopsies of the mediobasal hypothalamus were obtained from frozen AAV-injected 329 
brains. RNA was extracted using an RNeasy Micro Plus Kit (Qiagen), and cDNA was generated using a 330 
High-Capacity RNA-to-cDNA Kit (Applied Biosystems). Gene expression analysis was performed on an 331 
ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) using Taqman gene expression assays 332 
and Taqman® Universal Master Mix II (Applied Biosystems). Relative quantification was performed 333 
using standard curve analysis with normalization to the reference gene Hprt, and nomination of the 334 
vehicle group as a calibrator. The probes used were: Agrp, Mm00475829_g1; Npy, 335 
Mm00445771_m1; Pomc, Mm00435874_m1; Hprt, Mm03024075_m1. 336 
 337 
For all injected animals the presence of SaCas9 cDNA was determined in MBH micropunches using 338 
SYBR primers with GoTaq® qPCR Master Mix (Promega). Forward primer, 5’-339 
CAACAAGGTGCTCGTGAAGC-3’; reverse primer 5’-CGTCTTGCTGATTCTGCCCT-3’. Samples with Ct 340 
values >33 were determined to be undetectable due to a “missed” injection, and were excluded 341 
from all future analysis.  342 
 343 
2.13.    Statistics 344 
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All data are represented as mean ± SEM and results were considered to be statistically significant at 345 
P<0.05 unless otherwise stated. Statistical tests used were: unpaired t-test, Mann-Whitney unpaired 346 
t-test, one-way ANOVA, two-way ANOVA, or Pearson rank correlation unless otherwise stated. All 347 
statistical analysis and generation of graphs was performed using Graphpad Prism 6.0, or RStudio. 348 
 349 
 350 
3. Results 351 
3.1.    Chronic exogenous Cort treatment induces a metabolic phenotype 352 
Prior to the RNA-seq analysis of ARC tissue, mice were given Cort in the drinking water for periods of 353 
either 4 weeks or 2 days. The phenotypic results of chronic GC treatment were consistent with our 354 
previous studies using separate cohorts of mice [19,20]. After 4 weeks Cort treatment, there was 355 
raised circulating corticosterone levels (Supplemental Fig. 2a, Fig. 2b), hyperphagia (Supplemental 356 
Fig. 3a, Fig.3b), increased weight gain (Supplemental Fig. 3c), and elevated fat mass (Supplemental 357 
Fig. 3d). Our previous study demonstrated that chronic Cort treatment produced hyperglycaemia 358 
and hyperinsulinemia in the free-fed state [20]. Here we further these findings, showing that in the 359 
fasted state, blood glucose remained unaltered (Supplemental Fig. 3e), but circulating insulin was 360 
elevated (Supplemental Fig. 3f), indicating the presence of insulin resistance (Supplemental Fig. 3g). 361 
Phenotypic analysis of the 2 day cohort revealed an increase in food intake (Supplemental Fig. 4a) 362 
and brown adipose tissue mass, with no change in body weight, white adipose tissue, or 363 
gastrocnemius muscle mass (Supplemental Fig. 4b, Fig. 4c). Additionally, blood glucose was reduced 364 
(Supplemental Fig. 4d) and insulin was increased (Supplemental Fig. 4e).  365 
 366 
3.2.    Global transcriptomic response in the ARC to chronic Cort treatment 367 
To determine the transcriptomic response of the ARC to GC treatment, we utilized laser capture 368 
microdissection (Fig. 1a) in conjunction with RNA-seq. The specificity of dissections was confirmed 369 
by analyzing genes enriched in the ARC, and in the adjacent ventromedial hypothalamus (VMH). The 370 
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robust expression of Agrp, Npy, and Pomc was confirmed in all ARC replicates (Fig. 1b, c), which 371 
showed minimal expression of the VMH enriched genes Adcyap1, Cbln1, and Slit3 (Fig. 1b, c). 372 
Expression of the specific VMH marker gene, steroidogenic factor 1 (Nr5a1) was absent from all 4 373 
week replicates (Fig. 1c) and expressed at >550-fold lower than Agrp, Npy, or Pomc in all 2 day 374 
replicates (Fig. 1b), indicating a high level of accuracy when dissecting arcuate nuclei. After 4 weeks 375 
of GC treatment, the magnitude of gene changes in the ARC was greater than at 2 days, which is 376 
most clearly seen when the data are represented as scatter plots (Fig. 1d, e).  377 
 378 
3.3.    Transcriptomic changes in the ARC induced by 4 week chronic Cort treatment 379 
In 4 week treated samples, 15,719 genes were expressed in the ARC (>1 normalized CPM), of which 380 
12,013 were expressed in all samples. The number of genes differentially expressed with chronic 381 
Cort treatment was 224 (P<0.01; Fig. 2a, orange and blue dots), which was reduced to 43 when the 382 
data was corrected for multiple comparisons testing (Padj<0.1; Fig. 2a, blue dots). From these genes, 383 
21 were upregulated, and 22 were downregulated by Cort (Fig. 2b). Some of the most significantly 384 
altered genes are shown in Fig. 2c. Among those upregulated are a number of genes known to be 385 
regulated by GCs including Fam43a, Fam107a, Fam13a, and Mertk [27]. Downregulated genes 386 
included those involved in the regulation of energy balance, including Scly and Gpr12 [28,29].  In 387 
contrast to our previous work [19,20], Npy was markedly reduced and no increase in Agrp was 388 
observed, highlighting the issue that the fasting/refeeding (included to determine if glucose 389 
homeostasis was abnormal) has affected part of this pathway. We therefore focused on a new 390 
cohort of mice in which RNA-seq was performed on the ARC after 2 days of Cort treatment, when 391 
secondary effects, such as increased body weight, elevated fat mass, and chronic hyperinsulinemia, 392 
were limited.  393 
 394 
Gene ontology enrichment analysis was also performed to identify groups of functionally related 395 
genes. All significant (Padj<0.05) ontology terms for up- and downregulated genes at 4 weeks are 396 
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detailed in Supplemental Tables 3 and 4. Within the upregulated genes there was enrichment for 397 
those involved in metabolic processes, metal ion binding, and voltage gated potassium channel 398 
activity. Downregulated genes were enriched for those involved in cellular metabolic processes, and 399 
nervous system development. Among the downregulated genes, there was an overrepresentation of 400 
several pathways known to be regulated by GCs, including neurodevelopment, axon guidance, 401 
metabolism of amino acids, and regulation of the pro-inflammatory transcription factor NfKB. 402 
Among the predicted upstream regulators (Supplemental Table 7) were those known to be regulated 403 
by GR, including heat shock factor 1 (HSF1) and amyloid precursor protein (APP), as well as those 404 
involved in the control of feeding, such as forkhead box O3 (FOXO3) and FEV (also known as PET-1). 405 
 406 
3.4. Transcriptomic changes in the ARC after 2 days of Cort treatment 407 
After 2 days of Cort treatment, 231 genes were altered in the ARC (P<0.01; Fig. 3a, orange and blue 408 
dots), which was reduced to 46 when corrected for multiple testing (Padj<0.1; Fig. 3a, blue dots). Of 409 
these genes, 30 were upregulated, and 16 were downregulated with Cort treatment. To confirm 410 
these results, a selection of significant genes (P<0.01) were validated by qRT-PCR using laser 411 
captured ARC tissue from 2 day Cort treated mice. There was a clear correlation between expression 412 
data obtained using RNA-seq, and qRT-PCR (Fig. 3b; Supplemental Fig 5), confirming the 2 day RNA-413 
seq results. All of the transcripts that were altered in the ARC after 2 days of Cort treatment are 414 
shown in Fig. 3c, ranked according to their fold change. Among the upregulated genes were a 415 
number of known GC-regulated genes, such as Fam107a, Fkbp5, Glul, Mt2, Ociad2, and Paqr8 [27]. A 416 
selection of the most significantly altered genes is shown in Fig. 3d. Among these are the orexigenic 417 
neuropeptides Agrp and Nmb and the selenoproteins Dio2 and Sepp1.  418 
 419 
 Gene ontology enrichment analysis of upregulated genes showed an over-representation of those 420 
involved in hormone secretion, with an enrichment of genes localized at the neuronal synapse 421 
(Supplemental Table 5). Within the downregulated genes there was an enrichment of those involved 422 
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in neural development, synaptic transmission, calcium-dependent phospholipid binding, and 423 
locomotor activity (Supplemental Table 6). Similarly, the pathways altered included transmission 424 
across a chemical synapse and transmembrane transport of small molecules, suggesting altered 425 
neuronal activity. Upstream Regulator Analysis indicated that GR (Nr3c1) was among the top 426 
predicted higher order transcriptional regulators within the dataset (Supplemental Table 8), which 427 
also included APP and FEV/PET1, and these were common to the 4 week dataset.  428 
 429 
3.5.    Cort treated mice show increased Dio2 expression in the ARC 430 
An analysis of the available literature highlighted Dio2 as an interesting candidate gene for further 431 
study, since it increases the local availability of triiodothyronine (T3), which, in turn, increases food 432 
intake. Consistent with RNA-seq and qRT-PCR, mRNA expression of Dio2 in the MBH was increased 433 
after 2 days of Cort treatment when quantified by in situ hybridization (Fig. 4a, b). Dio2 expression 434 
appeared to be increased in both the tanycytes of the third ventricle and in the ARC (Fig. 4a, b). 435 
Elevated Dio2 (~1.6-fold) was also observed in the hypothalami of mice treated with Cort for 3 436 
weeks using the same paradigm (Supplemental Fig. 6; using 3 week hypothalamic RNA taken from 437 
Sefton et al., 2019 [20]), suggesting that the increase is sustained for the duration of Cort treatment. 438 
Furthermore, mRNA expression of the T3 responsive gene Hr [30] showed a trend towards an 439 
increase after 2 days of Cort (Fig. 4c, d).  440 
 441 
3.6.    Dio2 knockdown in the mediobasal hypothalamus using AAV-mediated CRISPR-Cas9 442 
To investigate the role of elevated Dio2 in the development of GC-induced metabolic effects, we 443 
next sought to knock down Dio2 in the MBH using AAV-mediated CRISPR-Cas9. First, two gRNAs 444 
were designed to target exon 1 of the Dio2 gene (Fig. 5a) and individually inserted into an SaCas9 445 
vector (Fig. 5b). The efficiency of gRNAs at generating insertion/deletion (InDel) mutations in the 446 
Dio2 gene was then assessed in vitro by transfection of the plasmid constructs into a murine 447 
embryonic fibroblast (3T3) cell line. Wild type amplicons (orange dots) and DNA containing InDels 448 
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(blue dots) were detected using ddPCR with probes designed over the gRNA cut sites (Fig. 5c), 449 
revealing gRNA efficiencies of 12.2% (gRNA1; Fig. 5d) and 15.8% (gRNA2; Fig. 5e).  450 
 451 
Vector constructs were then packaged into AAV2/8 virus particles, a serotype that efficiently 452 
transduces mouse glial cells [31], including astrocytes and tanycytes of the ARC [12]. In order to 453 
maximize knockdown efficiency both gRNAs were packaged and used in tandem. To generate 454 
knockdown of Dio2 in vivo, AAV-gRNA virus particles were stereotactically injected into the MBH of 455 
wild type C57Bl/6J mice. Successful bilateral injection was confirmed by the localized expression of 456 
SaCas9, as evidenced by anti-HA immunofluorescent staining (Fig. 5F). Confirmation of protein 457 
knockdown was prevented due to the lack of an anti-DIO2 antibody with suitable specificity. 458 
Similarly, CRISPR-edited alleles will still produce a non-functional mRNA transcript, making 459 
transcriptomic analysis of Dio2 not viable as an option for knockdown confirmation. However, the 460 
presence of InDels in DNA from laser captured MBH tissue was confirmed using ddPCR (Fig. 5g, 5h), 461 
indicating that AAV-gRNA viral particles are able to generate InDel mutations in vivo with high 462 
efficiency (~50%). Individual plots for each animal can be viewed in Supplemental Figure 7.  463 
 464 
3.7.    Determining if elevated Dio2 mediates GC-induced obesity and hyperphagia 465 
Using this model of Dio2 knockdown, we sought to determine the contribution of elevated Dio2 in 466 
the development of GC-induced hyperphagia and obesity. Accordingly, a separate cohort of mice 467 
were each injected with AAV-gRNA or AAV-null viral particles into the MBH and were subsequently 468 
challenged with Cort over 4 weeks. To confirm correct targeting of the virus, SaCas9 mRNA was 469 
quantified in punch biopsies taken of the MBH (Supplemental Fig. 8). Samples with absent 470 
expression (Ct > 33) were determined to be “missed” injections and were excluded from all further 471 
analysis (1 Ctrl-Veh, 1 Ctrl-Cort, 2 KO-Cort). 472 
 473 
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In agreement with previous data, exogenous Cort treatment increased food intake (Fig. 6a) and body 474 
weight (Fig. 6b); however, this effect was not attenuated with Dio2 knockdown (Fig. 6a and 6b). The 475 
increased body weight was likely due to increased fat mass as epididymal, subcutaneous, 476 
mesenteric, and brown adipose tissues were increased, while muscle weight decreased (Fig. 6c). 477 
Interestingly, the GC-induced increase in BAT weight was mildly attenuated with Dio2 knockdown 478 
(Fig. 6c). Consistent with 2 day RNA-seq data, Agrp mRNA expression was increased with Cort 479 
treatment in both control and Dio2 knockdown mice, however the amplitude of this increase was 480 
reduced by 56% with Dio2 knockdown (Fig. 6d). In agreement with our previous work[19,20], 481 
expression of Npy and Pomc was unaffected by chronic Cort treatment, and Dio2 knockdown had no 482 
additional effect (Fig. 6d). Chronic Cort treatment led to an increase in blood glucose after 28 days, 483 
measured in the free-fed state, which was not attenuated with knockdown of Dio2 (Fig. 6e).  484 
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4.    Discussion 485 
Long-term GC treatment was associated with the development of hyperphagia, obesity, and insulin 486 
resistance, as we have previously shown in other studies using this model [19,20]. We hypothesized 487 
that GC action within the ARC would contribute to these effects. However, targeting specific genes 488 
has not yet identified the contributing mechanisms [20]. Therefore, in the current study, we 489 
explored the underlying mechanisms using a broad approach and performed global transcriptomic 490 
analysis of the ARC, a valuable tool allowing for the accurate and unbiased identification of genes 491 
differentially regulated between treatments. Using this approach, we have identified ARC genes 492 
altered in response to both short- (2 day) and long-term (4 week) exogenous Cort treatment and 493 
have suggested both known and novel candidate genes that merit further investigation.  494 
 495 
In the current study, we identified 46 genes significantly altered in the ARC after 2 days of Cort 496 
treatment. Among these genes are previously identified GC target genes, including Fam107a and 497 
Fkbp5. Fam107a (also known as Tu3a and Drr1), is increased by both DEX [32] and prednisolone [33] 498 
and is reliant upon GR dimerization for its transactivation [33]. Similarly, Fkbp5 is a well-recognized 499 
GC target gene [34] and increased expression in the hypothalamus has been linked to obese 500 
phenotypes [35]. The presence of known GC-sensitive genes within the dataset validates the GC 501 
delivery method used and demonstrates that the ARC is transcriptionally sensitive to circulating GCs.  502 
 503 
In the 4 week dataset, 43 genes were significantly altered in the ARC. Surprisingly, only one gene, 504 
Fam107a, was altered in both 2 day and 4 week datasets. This may indicate that different 505 
mechanisms are active in the early and late stages of chronic Cort treatment. Indeed, this has been 506 
observed in another study of GC-regulated gene expression, showing that expression profiles differ 507 
based on the duration of GC exposure [36]. However, it is also likely that expression in the 4 week 508 
dataset has been influenced by the fast/refeed period, making comparisons between datasets 509 
difficult to interpret. Interestingly, FEV, a member of the highly conserved ETS family of transcription 510 
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factors was a predicted upstream regulator in both 2 day and 4 week datasets. FEV/PET1 is a key 511 
regulator of serotonergic neuronal development in the CNS [37], and has recently been identified as 512 
having a key role in food-related behavioral state switching and satiety [38]. This may represent a 513 
novel pathway through which GCs regulate food intake in the ARC.  514 
 515 
In addition to identifying well-established GC-responsive genes, we observed a change in a range of 516 
energy regulatory genes. There was a strong increase in Nmb, a bombesin-related peptide that 517 
potently activates AgRP/NPY neurons in the ARC [39] and may contribute to the increase in food 518 
intake. Previous studies indicate that Nmb is negatively regulated in the ARC by the anorexigenic 519 
hormone leptin [40] and thus may represent a mechanism mediating the bidirectional control of 520 
food intake in response to peripheral hormonal cues. Other notable genes that were downregulated 521 
with Cort treatment are Gabra3 and Gabrq, two subunits of the GABAA receptor. Within the ARC, 522 
GABA receptors have been implicated in several critical homeostatic mechanisms, including food 523 
intake, thermoregulation, and foraging [41]. We also observed an increase in the selenoprotein, 524 
Sepp1, a class of protein increasingly believed to play a key role in hypothalamic control of energy 525 
balance [42]. Indeed, elevated serum selenoprotein-P (encoded by Sepp1) has been associated with 526 
obesity and diabetes in humans, and overexpression both in vitro and in vivo leads to insulin 527 
resistance [43].  528 
 529 
Among the transcripts altered in response to Cort treatment, Dio2 stood out, both by its degree of 530 
upregulation, its restricted localization to the MBH [44], and by the growing body of evidence 531 
implicating Dio2 and T3 in the central control of energy balance [45–49]. While previous studies have 532 
hinted that GCs may regulate Dio2 [50], here we provide the first conclusive evidence that 533 
exogenous Cort increases hypothalamic Dio2 expression. Within the hypothalamus, Dio2 is highly 534 
localized to the tanycytes and astrocytes of the ARC [44] and increases the local availability of T3 535 
[51], which then regulates neuronal gene expression in a paracrine manner [52]. Modulation of 536 
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hypothalamic T3 can have a significant impact on food intake and metabolism. Endogenously 537 
elevated T3 acts as a key seasonal switch between catabolic and anabolic states in natural animal 538 
models of obesity, such as the Siberian hamster [45,46]. Similarly, in other rodent models, elevated 539 
hypothalamic T3 leads to an increase in food intake [47–49]. Specifically within the ARC, T3 increases 540 
food intake via two independent mechanisms. Firstly, in fasted mice DIO2-derived T3 induces 541 
mitochondrial upregulation of UCP2 in AgRP/NPY neurons, thereby elevating their activity and 542 
increasing food intake [47]. Secondly, in the context of hyperthyroidism, T3 increases mTOR 543 
signaling in the ARC, leading to an increase in food intake [49]. It must be noted that in another 544 
study, intra-ARC injection of T3 did not alter food intake [53]. Thus while the appetitive action of 545 
hypothalamic T3 has been identified under specific circumstances, the full range of molecular 546 
mechanisms governing T3 control of food intake have yet to be elucidated.  547 
 548 
To investigate the effects of Dio2 on Cort-induced metabolic dysfunction, we used AAV-targeted 549 
CRISPR-Cas9 to specifically knockdown Dio2 in the MBH before treating with Cort for 4 weeks. This 550 
knockdown of Dio2 did not attenuate GC-induced hyperphagia or body weight gain as expected. One 551 
possibility is that the absence of a change in food intake is due to the duration of GC treatment. To 552 
date, studies that have observed elevated T3-induced food intake have done so in an acute setting. 553 
A single bolus injection of T3 into the ARC increased food intake over 12 hours [49]. Similarly, global 554 
knockout of Dio2 abolishes the fasting-induced increase in hypothalamic T3 levels, which is 555 
associated with a blunted refeeding response, only in the first 30 minutes after a 24 hr fast [47]. 556 
Therefore, while elevated T3 increases food intake in an acute setting, this may not occur with 557 
chronic elevation. Indeed, differing acute and chronic effects of T3 were observed in other 558 
hypothalamic nuclei, as acute [54] but not chronic [55], delivery of T3 into the PVN raised blood 559 
glucose levels. 560 
 561 
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In accordance with our previous data [19,20], GC treatment in the Cort-treated mice induced a 562 
strong increase in hypothalamic Agrp. This increase was attenuated (by 56%) in mice with Dio2 563 
knockdown, suggesting that the GC-induced increase in Agrp is mediated , at least partially, by 564 
increased hypothalamic Dio2 expression. Recent work from our lab has shown that Agrp deletion 565 
had little effect on Cort induced metabolic abnormalities [20], and as such this reduction in AgRP 566 
would not be expected to have a metabolic effect. The attenuated increase in Agrp transcript with 567 
Dio2 knockdown is in agreement with previous evidence indicating that thyroid hormones increase 568 
the expression of Agrp [49,56,57]. It would therefore be expected that Dio2 knockdown would 569 
decrease T3 availability, and could thus be the mechanism limiting the GC-induced increase in Agrp. 570 
We cannot exclude the possibility that this decrease is only partial due to incomplete knockdown of 571 
Dio2 (50% editing efficiency); however, it may also suggest that GCs regulate Agrp expression 572 
through multiple mechanisms. Indeed, there is a GC response element (GRE) in the Agrp gene [58]. 573 
Therefore, it is likely that GCs increase Agrp both via direct action, and indirectly via a Dio2-mediated 574 
increase in local T3 availability. This hypothesis is supported by evidence that DIO2-producing glial 575 
cells are in direct contact with AgRP/NPY neurons [47], exposing them to locally formed T3.  576 
 577 
5. Conclusion 578 
This genome-wide analysis has identified the transcriptomic response of the hypothalamic ARC to 579 
chronic exogenous Cort treatment. The range of both known and novel candidate genes indicates 580 
that there is the potential for multiple mechanisms to contribute to the metabolic abnormalities 581 
observed with Cort treatment. Dio2 was an obvious candidate given its robust elevation with Cort 582 
treatment and its clear links to feeding and metabolism. However, knockdown of Dio2 using AAV-583 
mediated CRISPR-Cas9 vectors targeted to the MBH conferred no protection from GC-induced 584 
hyperphagia or obesity in this setting, providing evidence that other mechanisms mediate the 585 
metabolic sequelae resulting from chronic GC treatment.   586 
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Figure Legends: 800 
 801 
Fig. 1: Validation of RNA-seq datasets from the arcuate nuclei of 2 day and 4 week Cort treated 802 
mice. (a) Representative hypothalamic sections stained with cresyl violet to allow visualization of 803 
hypothalamic cytoarchitecture and isolation of the ARC by laser capture microdissection. Scale bar = 804 
300μm. (b) Heatmap showing ARC and VMH enriched genes across all 2 day (n = 5/group) and (c) 4 805 
week (n = 5/group) treated samples. (d) Scatter plot showing the expression and fold change of all 806 
genes in 2 day (n = 3-4/group), and (e) 4 week treated (n = 3-4/group) datasets. (d, e) Red dots, 807 
upregulated genes (P<0.01); blue dots, downregulated genes (P<0.01). Wald test.  808 
 809 
Fig. 2: Global gene expression changes in the arcuate nucleus of 4 week Cort treated mice. (a) 810 
Volcano plot of all genes found by RNA-seq. Orange (P<0.01) and blue (Padj<0.1) dots represent 811 
genes with significant change in expression. The position of select genes is illustrated by the gene 812 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
symbol (n = 3-4/group). (b) Heatmap showing all 43 genes differentially expressed (Padj) in the ARC 813 
after 4 weeks of Cort treatment. Left panel, each row corresponds to transcripts where the 814 
expression is normalized to the mean expression on the row (Z-scaled). Right panel, the mean 815 
expression across all samples [Log2(MeanCPM)], fold change [Log2(FC)], and significance for each 816 
gene [-Log10(Padj)] (n = 3-4/group). (c) Examples of different genes altered in the ARC with Cort 817 
treatment. White bars, vehicle (Veh); black bars, 75µg/ml corticosterone (Cort) treated (n = 3-818 
4/group; Fam43a, Padj = 9.54e-8; Fam107a, Padj = 4.63e-4; Fam13a, Padj = 0.0073; Scly, Padj = 819 
0.014; Npy, Padj = 1.75e-7; Gpr12, Padj = 0.071). *Padj<0.1, **Padj<0.01, ***Padj<0.001. (a) Wald 820 
test, (b, c) Benjamini-Hochberg adjusted P value. 821 
 822 
Fig. 3: Global gene expression changes in the arcuate nucleus of 2 day Cort treated mice. 823 
(a) Volcano plot of all genes found by RNA-seq. Orange (P<0.01) and blue (Padj<0.1) dots represent 824 
genes with significant change in expression. The position of select genes is illustrated by the gene 825 
symbol (n = 3-4/group). (b) Biological and technical correlation between RNA-seq and qRT-PCR in 37 826 
differentially expressed genes (RNA-seq, n = 3-4/group; qRT-PCR, n = 6-7/group). (c) Heatmap 827 
showing all 46 genes differentially expressed (Padj) in the ARC after 2 days of Cort treatment. Left 828 
panel, each row corresponds to transcripts where the expression is normalized to the mean 829 
expression on the row (Z-scaled). Right panel, the mean expression across all samples 830 
[Log2(MeanCPM)], fold change [Log2(FC)], and significance for each gene [-Log10(Padj)] (n = 3-831 
4/group). (d) Examples of genes altered in the ARC with Cort treatment (n = 3-4/group; Agrp, Padj = 832 
1.21e-6; Nmb, Padj = 0.016; Dio2, Padj = 0.031; Sepp1, Padj = 1.24e-4; Fam107a, Padj = 3.52e-7; Fry, 833 
Padj = 0.0995; Gabra3, Padj = 0.061; Gabrq, Padj = 0.089 ). White bars, vehicle (Veh); black bars, 834 
75µg/ml corticosterone (Cort) treated. *Padj<0.1, **Padj<0.01, ***Padj<0.001. (a) Wald test, (b) 835 
Pearson’s correlation, (c, d) Benjamini-Hochberg adjusted P value. 836 
 837 
Fig. 4: Cort treatment increases Dio2 mRNA expression in the mediobasal hypothalamus.  838 
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Mice were treated with either corticosterone or vehicle in the drinking water for 2 days. (a, c) 839 
Representative autoradiographic images and (b, d) densitometric quantification of coronal brain 840 
sections incubated with riboprobes targeting Dio2 and Hr, respectively (n = 6/group; Dio2: P = 841 
0.0022; Hr: P = 0.0931). White bars, vehicle (Veh); black bars, 75µg/ml corticosterone (Cort) treated. 842 
**P<0.01. (b, d) Mann-Whitney test.   843 
 844 
Fig. 5: Validation of AAV-gRNA for targeted disruption of Dio2 in the mediobasal hypothalamus. 845 
(a) Schematic representation of the Dio2 locus showing the location of the gRNA target sequences. 846 
Target sequence in blue, protospacer adjacent motif sequence in red. (b) Schema of the single vector 847 
AAV delivery construct containing SaCas9 and gRNA. (c) In vitro confirmation of gRNA efficiency 848 
using droplet digital PCR (ddPCR; n = 3-4/group). (d) Quantification of gRNA1 (#1) editing frequency 849 
(n = 3-4/group; F2, 7 = 9.057, P = 0.0114). (e) Quantification of gRNA2 (#2) editing efficiency (n = 3-850 
4/group; F2, 7 = 21.62, P = 0.001). (f) Representative immunofluorescent images showing bilateral 851 
targeting of the MBH. Scale bar = 500μm. (g) Confirmation and (h) quantification of in vivo AAV-852 
gRNA gene editing efficiency (n = 4-6/group; P = 0.0095). All ddPCR scatter plots represent merged 853 
replicates. Reference probe, FAM; InDel+ probe, Hex. Pink bars indicate manually set thresholds. 854 
Orange dots, wild type DNA; blue dots, DNA containing InDels; grey dots; empty droplets. *P<0.05, 855 
**P<0.01 vs Ctrl (no gRNA).  
#
P<0.05 vs gRNA2, 
$$
P<0.01 vs gRNA1, ***P<0.001. (d, e) One-way 856 
ANOVA with Tukey’s post-hoc comparison, (h) Mann-Whitney test.  857 
 858 
Fig. 6: Targeted knockdown of Dio2 in the MBH does not alleviate the metabolic effects of chronic 859 
Cort treatment. (a) Percent change in food intake (n = 9-14/group; time: F8, 320 = 19.39, P <0.0001; 860 
interaction: F24, 320 = 5.466, P <0.0001; treatment: F3, 40 = 34.52, P <0.0001) and (b) body weight across 861 
the 4 week Cort treatment period (n = 9-14/group; time: F8, 320 = 268.6, P <0.0001; interaction: F24, 320 862 
= 21.23, P <0.0001; treatment: F3, 40 = 10.52, P <0.0001). (c) Individual adipose tissue bed and muscle 863 
weight after 4 weeks of Cort treatment (n = 8-14/group; Epi: F3, 38 = 31.22, P <0.0001; Subcut: F3, 39 = 864 
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85.87, P <0.0001; Mes: F3, 38 = 39.67, P <0.0001; BAT: F3, 39 = 88.7, P <0.0001; Muscle: F3, 39 = 1.945, P = 865 
0.1382). (d) Expression of ARC neuropeptides in MBH micropunches after 4 weeks of Cort treatment 866 
(n = 8-14/group; Agrp: F3, 37 = 26.69, P <0.0001; Npy: F3, 38 = 0.4874, P = 0.6931; Pomc: F3, 37 = 0.379, P 867 
= 0.7687). (e) Blood glucose measurements (n = 9-14/group; time: F3, 120 = 10.7, P <0.0001; 868 
interaction: F9, 120 = 6.501, P <0.0001; treatment: F3, 40 = 4.992, P = 0.0049). Epi, epididymal; Subcut, 869 
subcutaneous; Mes, mesenteric. Ctrl, AAV-Null injected; KO; AAV-gRNA injected; Veh, 1% ethanol; 870 
Cort, 75μg/ml corticosterone. a, significance vs Ctrl-Veh; b, significance vs KO-Veh. *P<0.05, 871 
**P<0.01, ***P<0.001. (a, b, e) Two-way ANOVA with Tukey’s post-hoc compassion (c, d) one-way 872 
ANOVA with Tukey’s post-hoc comparison.  873 
 874 
Supplemental Figure 1: Principal component analysis. Outlier samples were detected based on 875 
global transcriptomic profiles in principal component analysis (PCA) plots for (a) 2 day (n=5) and (b) 4 876 
week datasets (n=5). Two vehicle and one Cort outlier were identified in each group (marked with 877 
stars; 2 day: C07, C08, C09; 4 week: C01, C05, C06). Vehicle samples are represented in red, Cort 878 
samples in cyan. 879 
 880 
Supplemental Figure 2: The effects of exogenous Cort delivery on levels of circulating 881 
corticosterone. (a) Circulating corticosterone concentrations at the peak (n = 8-10/group; t16 = 9.84, 882 
P <0.0001) and (b) nadir of the endogenous rhythm (n = 10/group; t18 = 8.065, P <0.0001). White 883 
bars, vehicle (Veh); Black bars, 75µg/ml corticosterone (Cort) treated. ZT1, 7am; ZT13, 7pm. 884 
***P<0.001. (a, b) Unpaired student’s t-test.  885 
 886 
Supplemental Figure 3:  The phenotypic effects of exogenous Cort treatment over 4 weeks. (a) 887 
Daily food intake (n = 10/group; time: F8, 144 = 3.01, P = 0.0037; interaction: F8, 144 = 1.422, P = 0.1921; 888 
treatment: F1, 18 = 26.03, P <0.0001) and (b) cumulative food intake across the treatment period 889 
(n=10/group; time: F8, 144 = 1572, P <0.0001; interaction: F8, 144 = 14.84, P <0.0001; treatment: F1, 18 = 890 
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9.297, P = 0.0069). (c) Body weight across the treatment period (n = 10/group; time: F8, 144 = 118.3, P 891 
<0.0001; interaction: F8, 144 = 41.37, P <0.0001; treatment: F1, 18 = 31.5, P <0.0001). (d) Epididymal, 892 
subcutaneous and mesenteric adipose tissue weights at the time of cull (n = 9-10/group; Epi, t18 = 893 
5.942, P <0.0001; Subcut, t17 = 11.36, P <0.0001; Mes, t18 = 3.713, P = 0.0016). (e) Fasted blood 894 
glucose (n = 9-10/group; t17 = 0.04999, P = 0.9607), (f) insulin (n=10/group; t18 = 3.623, P = 0.0019), 895 
and (g) HOMA-IR after 29 days of Cort treatment (n = 10/group; t18 = 3.364, P = 0.0035). Epi, 896 
epididymal; Subcut, subcutaneous; Mes, mesenteric. White bars, vehicle (Veh); Black bars, 75µg/ml 897 
corticosterone (Cort) treated. *P<0.05, **P<0.01, ***P<0.001. (a-c) Two-way ANOVA with Sidak’s 898 
post-hoc comparison, (d-g) unpaired student’s t-test.  899 
 900 
Supplemental Figure 4:  The phenotypic effects of exogenous Cort treatment over 2 days. (a) Total 901 
food intake (n=9-10/group; P = 0.0041) and (b) body weight after the 2 day treatment period (n = 9-902 
10/group; t17 = 0.0081, P = 0.9936). (c) Individual adipose tissue bed and muscle weights at the time 903 
of cull (n = 9-10/group; Epi: t17 = 1.726, P = 0.1024; Subcut: t18 = 1.746, P = 0.0979; Mes: t17 = 0.5725, 904 
P = 0.5745; BAT: t16 = 3.985, P = 0.0011; Muscle: t16 = 1.991, P = 0.0639). (d) Circulating blood glucose 905 
(n = 10/group; t18 = 2.109, P = 0.0492) and (e) insulin after 2 days of treatment (n = 9/group; t16 = 906 
2.202, P = 0.0427). Epi, epididymal; Subcut, subcutaneous; Mes, mesenteric. White bars, vehicle 907 
(Veh); Black bars, 75µg/ml corticosterone (Cort) treated. *P<0.05, **P<0.01, ***P<0.001. (a) Mann-908 
Whitney test, (b-e) Unpaired student’s t-test.  909 
 910 
Supplemental Figure 5: Validation of 2 day RNA-seq results. Validation of 2 Day RNA-seq results by 911 
qRT-PCR in laser capture microdissected ARC tissue from 2 day Cort treated mice. . Each gene is 912 
expressed as fold change relative to the vehicle control, represented by the horizontal dotted line (n 913 
= 6-7/group). Red bars = genes up regulated in RNA-seq; blue bars = genes down regulated in RNA-914 
seq (n = 6-7/group). *P<0.05, **P<0.01, ***P<0.001. Unpaired student’s t-test. 915 
 916 
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 917 
Supplemental Figure 6:  Dio2 expression in whole hypothalami following 3 week chronic Cort 918 
treatment. Dio2 mRNA expression is increased in whole hypothalami after 3 weeks of oral Cort 919 
treatment (n = 8/group; P = 0.0002). White bar, vehicle (Veh), black bar, 75µg/ml corticosterone 920 
(Cort) treated. ***P<0.001. Mann-Whitney test. 921 
 922 
Supplemental Figure 7: Individual ddPCR plots. DNA was extracted from the laser capture 923 
microdissected mediobasal hypothalamic tissue of AAV-null and AAV-gRNA injected mice. All plots 924 
represent individual replicates from each animal. Reference probe, FAM; InDel+ probe, Hex. Pink 925 
bars indicate manually set thresholds. Orange dots, wild type DNA; blue dots, DNA containing InDels; 926 
grey dots; empty droplets. 927 
 928 
Supplemental Figure 8:  SaCas9 expression in MBH micropunches. Ct values of SaCas9 mRNA 929 
measured in micropunches taken from the mediobasal hypothalami of AAV-injected mice. Dashed 930 
line indicates the cutoff Ct vale of 33. All samples above this threshold were determined to be 931 
“missed” injections and were excluded from all subsequent analysis. Ct, cycle threshold (n = 9-932 
14/group). 933 
 934 
Supplemental Table 1: Total reads and mapped reads for 2 day and 4 week RNA-seq samples 935 
 936 
Supplemental Table 2: Primers used for multiplex qRT-PCR 937 
 938 
Supplemental Table 3: Gene ontology enrichment analysis of genes upregulated after 4 weeks of 939 
Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s 940 
exact with FDR multiple test correction).        941 
 942 
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Supplemental Table 4: Gene ontology enrichment analysis of genes downregulated after 4 weeks of 943 
Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s 944 
exact with FDR multiple test correction). 945 
 946 
Supplemental Table 5:  Gene ontology enrichment analysis of genes upregulated after 2 days of Cort 947 
treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s exact 948 
with FDR multiple test correction).  949 
 950 
Supplemental Table 6: Gene ontology enrichment analysis of genes downregulated after 2 days of 951 
Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s 952 
exact with FDR multiple test correction).  953 
 954 
Supplemental Table 7: Upstream regulator analysis of genes altered after 4 weeks of Cort 955 
treatment. (Ingenuity Pathway Analysis, www.qiagen.com/ingenuity; Fisher’s exact test with 956 
Benjamini-Hochberg Correction).  957 
 958 
Supplemental Table 8: Upstream regulator analysis of genes altered after 2 days of Cort treatment. 959 
(Ingenuity Pathway Analysis, www.qiagen.com/ingenuity; Fisher’s exact test with Benjamini-960 
Hochberg Correction). 961 
            962 
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Group Treatment Sample Total reads Mapped Reads Proportion mapped
1 2 day Vehicle L2DRBC02 22799085 16325733 0.7161
2 2 day Vehicle L2DRBC04 19728104 15180633 0.7695
3 2 day Vehicle L2DRBC05 23727331 18095450 0.7626
4 2 day Vehicle L2DRBC07 34592437 25729016 0.7438
5 2 day Vehicle L2DRBC09 22725545 16950112 0.7459
6 2 day Cort L2DRBC01 31836343 23753772 0.7461
7 2 day Cort L2DRBC03 16889550 12478319 0.7388
8 2 day Cort L2DRBC06 29470841 22283638 0.7561
9 2 day Cort L2DRBC08 32278099 23644266 0.7325
10 2 day Cort L2DRBC10 12651742 9619222 0.7603
11 4 week Vehicle L2DRBC01 10390654 9000713 0.8662
12 4 week Vehicle L2DRBC02 12499646 10908631 0.8727
13 4 week Vehicle L2DRBC03 11545773 10069570 0.8721
14 4 week Vehicle L2DRBC04 12109026 10382489 0.8574
15 4 week Vehicle L2DRBC05 11830833 10430228 0.8816
16 4 week Cort L2DRBC06 15648378 13172799 0.8418
17 4 week Cort L2DRBC07 22659843 20033465 0.8841
18 4 week Cort L2DRBC08 22359706 19839937 0.8873
19 4 week Cort L2DRBC09 9666145 8621935 0.8920
20 4 week Cort L2DRBC10 16021888 14099709 0.8800
Supplemental Table 1: Total reads and mapped reads for 2 day and 4 week RNA-seq samples
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Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
Acvr1c GCTTTCCATAGCGAGTGGTC ATCTCGGTGAGCAATAGCAG
Agrp GGCCTCAAGAAGACAACTGC GCAAAAGGCATTGAAGAAGC
Arhgef3 GAGACAGGAGGCGATCTTTGA AGTTTCAGCATGGGGTCGTG
Cdkn1a GACCAGCCTGACAGATTTCTA TGGGCACTTCAGGGTTTTCT
Cited1 ATGCCAACCAGGAGATGAAC AGGATGCAGGTTGAAGGATG
Dio2 CCACCTGACCACCTTTCACT TGGTTCCGGTGCTTCTTAAC
Elovl6 AGAGGCGCAGAGAACACGTA GGATGGCTTCGTTCTCGTTG
Fam107a TCATCAAACCCAAGAAGCTG CTCAGGCTTGCTGTCCATAC
Ghr AGCCTCGATTCACAAGTGTCG GATGACCAATTCTTGCAGCTTG
Ghsr AGATCGCGCAGATCAGTCAG GTATTGATGCTCGACTTTGTCCA
Gpr6 CTTAGCAGCCACCAGAAAGG TGGCTACCCACCACACAATA
Igf1r TTGTGTTGTTCGTCCGGTGTG ATGTGCCCAAGTGTGTGCG
Lamp2 TAGGAGCCGTTCAGTCCAAT GTGTGTCGCCTTGTCAGGTA
Lepr GACTGAATTTCCAAAAGCCTGAA GCTCCAGAAGAAGAGGACCAA
Nmb CCTGCTCTTCGCATTGTTCG AAGTGACCGGTCGCCCA
Npy ATGCTAGGTAACAAGCGAATGG TGTCGCAGAGCGGAGTAGTAT
Oxt CAGCCCGGATGGCTGC TTCCCAGAAAGTGGGCTCAG
Pomc ATGCCGAGATTCTGCTACAGT TCCAGCGAGAGGTCGAGTTT
Rgs2 GAGGAGAAGCGGGAGAAAAT CCAGGAGCAGAGGAATTCTG
Sepp1 CCTTGGTTTGCCTTACTCCTTCC TTTGTTGTGGTGTTTGTGGTGG
Serpina3n CCCTGAGGAGTGGAAGAAT CCTGATGCCCAGCTTTGAAA
Timp4 GACCCTGCTGACACTCAAAAAC GGAAGAGTCAAATGGCGTGTAG
Trib1 GCAGATTGTTTCCGCCGTC CAGTCTAAGCTGGGTTCTCTCC
Ahi1 TCTCAAAAGCAGTCGCTCAGT CCGGCTCGCTTTTCTTTGTC
Bsn TCTGGTGATTGTGTCCAGAAGG GTTTGCCAGCTTGTAGATGCGTT
Chd5 TGCAACCATCCGTACCTCTTCC TCAGCACTCTGTGCCCTTCATC
Cntn5 TATCCCAAGAGACAGGCAACC TCCCATCACACCATCATTTCGC
Gabra3 CTTGGGAAGGCAAGAAGGTA CCTTGGCCAGATTGATAGGA
Gabre GGCCTCTGTAGGGGTCAGTT AGTGCAGAAGCACAAGACGA
Gabrq CTCACCACCATTCTCTCCTG CGATGGTAGTCAGGACAAGG
Gap43 GGAGAAAGACGCTGTAGACG AGGAGAGACAGGGTTCAGGT
Hdac5 AGCCCTTGGATGAAGCAGTC CTCCAGTGTTTGCTCTGGATCT
Htr2c CGTTTGGGCAATATCAATAGGAGT GCTTTCGTCCCTCAGTCCAA
Pclo CCTCCATGCACAGGAAACAAG TTGCTGTGGAGCCTGACTAC
Pnpla6 AGCACTCGGAACTGACCAAC GAGCGTGGGACCAATAGCTT
Slc17a6 CAAGGACTTGTGGAGGGTGT GCAATGACTGCTCCAGCATA
Slit2 GAGTTTGTCTGCAGTGATGAGG CAGTGAGACCTTTCCCTCGG
Actb ACCTCCTACAATGAGCTGC TGCCAATAGTGATGACCT
B2m TAAGCATGCCAGTATGGCCG TGTCTCGATCCCAGTAGACG
Gapdh TGACATCAAGAAGGTGGTGAA CCCTGTTGCTGTAGCCGTATTC
Hprt AGGACTGAAAGACTTGCTCG GCTGACCTGCTGGATTACAT
Tbp GGGAGAATCATGGACCAGAA GATGGGAATTCCAGGAGTCA
Upregulated genes
Downregulated Genes
Housekeeper Genes
Supplemental Table 2: Primers used for multiplex qRT-PCR
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ACCEPTED MANUSCRIPTMolecular Function No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Voltage-Gated Potassium Channel Activity (Go:0005249) 91 9 1.62 + 5.55 6.63E-05 3.03E-02
Monovalent Inorganic Cation Transmembrane Transporter Activity (Go:0015077) 355 19 6.33 + 3 3.77E-05 2.15E-02
Inorganic Cation Transmembrane Transporter Activity (Go:0022890) 556 24 9.92 + 2.42 1.31E-04 4.99E-02
Transferase Activity (Go:0016740) 2295 72 40.93 + 1.76 2.91E-06 3.32E-03
Metal Ion Binding (Go:0046872) 3410 98 60.81 + 1.61 1.60E-06 2.44E-03
Cation Binding (Go:0043169) 3509 100 62.58 + 1.6 1.56E-06 3.55E-03
Ion Binding (Go:0043167) 5348 132 95.37 + 1.38 4.19E-05 2.12E-02
Binding (Go:0005488) 12812 274 228.48 + 1.2 3.65E-06 3.33E-03
Molecular_Function (Go:0003674) 20290 384 361.83 + 1.06 2.09E-05 1.36E-02
Transmembrane Signaling Receptor Activity (Go:0004888) 2090 16 37.27 - 0.43 7.84E-05 3.25E-02
Unclassified (Unclassified) 1972 13 35.17 - 0.37 2.09E-05 1.59E-02
Olfactory Receptor Activity (Go:0004984) 1096 0 19.55 -  < 0.01 4.21E-09 1.92E-05
Biological Process No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Monovalent Inorganic Cation Transport (Go:0015672) 320 19 5.71 + 3.33 9.69E-06 2.14E-02
Inorganic Cation Transmembrane Transport (Go:0098662) 393 21 7.01 + 3 1.52E-05 2.13E-02
Cation Transmembrane Transport (Go:0098655) 419 21 7.47 + 2.81 3.71E-05 3.58E-02
Inorganic Ion Transmembrane Transport (Go:0098660) 444 22 7.92 + 2.78 2.87E-05 2.95E-02
Cellular Macromolecule Metabolic Process (Go:0044260) 5124 130 91.38 + 1.42 1.11E-05 1.90E-02
Cellular Metabolic Process (Go:0044237) 7347 180 131.02 + 1.37 4.99E-07 2.57E-03
Nitrogen Compound Metabolic Process (Go:0006807) 7010 166 125.01 + 1.33 2.03E-05 2.61E-02
Primary Metabolic Process (Go:0044238) 7548 177 134.6 + 1.31 1.40E-05 2.17E-02
Organic Substance Metabolic Process (Go:0071704) 7920 183 141.24 + 1.3 2.22E-05 2.64E-02
Metabolic Process (Go:0008152) 8386 191 149.55 + 1.28 2.81E-05 3.10E-02
Cellular Process (Go:0009987) 14173 297 252.75 + 1.18 3.19E-06 8.21E-03
Biological_Process (Go:0008150) 20434 388 364.4 + 1.06 1.04E-06 3.21E-03
Sensory Perception (Go:0007600) 1576 8 28.1 - 0.28 9.85E-06 1.90E-02
Unclassified (Unclassified) 1828 9 32.6 - 0.28 1.04E-06 4.02E-03
Sensory Perception Of Smell (Go:0007608) 1095 1 19.53 - 0.05 9.19E-08 7.09E-04
Sensory Perception Of Chemical Stimulus (Go:0007606) 1194 1 21.29 - 0.05 1.97E-08 3.04E-04
Cellular Component No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Voltage-Gated Potassium Channel Complex (Go:0008076) 79 9 1.41 + 6.39 2.40E-05 2.56E-03
Potassium Channel Complex (Go:0034705) 88 10 1.57 + 6.37 8.66E-06 1.11E-03
Cation Channel Complex (Go:0034703) 203 14 3.62 + 3.87 3.15E-05 3.18E-03
Ion Channel Complex (Go:0034702) 275 15 4.9 + 3.06 2.01E-04 1.61E-02
Transmembrane Transporter Complex (Go:1902495) 289 15 5.15 + 2.91 3.33E-04 2.37E-02
Transporter Complex (Go:1990351) 296 15 5.28 + 2.84 4.23E-04 2.80E-02
Plasma Membrane Protein Complex (Go:0098797) 521 21 9.29 + 2.26 7.01E-04 4.21E-02
Neuronal Cell Body (Go:0043025) 680 26 12.13 + 2.14 3.73E-04 2.56E-02
Golgi Apparatus (Go:0005794) 1348 47 24.04 + 1.96 1.86E-05 2.11E-03
Neuron Projection (Go:0043005) 1435 50 25.59 + 1.95 8.46E-06 1.16E-03
Membrane Protein Complex (Go:0098796) 1095 37 19.53 + 1.89 2.68E-04 1.98E-02
Somatodendritic Compartment (Go:0036477) 990 33 17.65 + 1.87 8.40E-04 4.74E-02
Neuron Part (Go:0097458) 1718 56 30.64 + 1.83 1.77E-05 2.12E-03
Plasma Membrane Bounded Cell Projection (Go:0120025) 2142 62 38.2 + 1.62 2.13E-04 1.63E-02
Cell Projection (Go:0042995) 2327 67 41.5 + 1.61 1.34E-04 1.12E-02
Cytoplasmic Part (Go:0044444) 8233 205 146.82 + 1.4 4.78E-09 9.18E-07
Nucleus (Go:0005634) 6641 164 118.43 + 1.38 1.80E-06 3.14E-04
Intracellular Membrane-Bounded Organelle (Go:0043231) 10081 247 179.78 + 1.37 2.59E-11 5.53E-09
Cytoplasm (Go:0005737) 10672 260 190.31 + 1.37 3.52E-12 1.13E-09
Membrane-Bounded Organelle (Go:0043227) 10788 262 192.38 + 1.36 3.57E-12 9.80E-10
Intracellular Organelle (Go:0043229) 11737 279 209.31 + 1.33 2.23E-12 8.56E-10
Intracellular Part (Go:0044424) 13409 315 239.12 + 1.32 9.66E-16 1.86E-12
Protein-Containing Complex (Go:0032991) 5241 123 93.46 + 1.32 8.24E-04 4.79E-02
Organelle (Go:0043226) 11981 281 213.66 + 1.32 9.16E-12 2.20E-09
Intracellular (Go:0005622) 13486 315 240.5 + 1.31 3.15E-15 3.02E-12
Organelle Part (Go:0044422) 7293 167 130.06 + 1.28 1.26E-04 1.10E-02
Intracellular Organelle Part (Go:0044446) 7029 159 125.35 + 1.27 4.81E-04 3.08E-02
Cell Part (Go:0044464) 15775 345 281.32 + 1.23 7.87E-14 5.04E-11
Cell (Go:0005623) 15778 345 281.37 + 1.23 7.90E-14 3.79E-11
Cellular_Component (Go:0005575) 20724 390 369.57 + 1.06 4.59E-06 7.34E-04
Extracellular Region (Go:0005576) 2451 21 43.71 - 0.48 1.21E-04 1.11E-02
Extracellular Region Part (Go:0044421) 1891 16 33.72 - 0.47 6.99E-04 4.33E-02
Extracellular Space (Go:0005615) 1636 10 29.17 - 0.34 5.29E-05 5.08E-03
Unclassified (Unclassified) 1538 7 27.43 - 0.26 4.59E-06 6.78E-04
Supplemental Table 3: Gene ontology enrichment analysis of genes upregulated after 4 weeks of Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s 
exact test with FDR multiple test correction).
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Ion Binding (Go:0043167) 5348 92 60.78 + 1.51
Binding (Go:0005488) 12812 196 145.6 + 1.35
Protein Binding (Go:0005515) 8720 132 99.1 + 1.33
Olfactory Receptor Activity (Go:0004984) 1096 0 12.46 -  < 0.01
Biological Process No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment
Nervous System Development (Go:0007399) 2106 51 23.93 + 2.13
System Development (Go:0048731) 4022 73 45.71 + 1.6
Cellular Component Organization Or Biogenesis (Go:0071840) 5061 90 57.52 + 1.56
Multicellular Organism Development (Go:0007275) 4585 81 52.11 + 1.55
Cellular Component Organization (Go:0016043) 4876 86 55.41 + 1.55
Anatomical Structure Development (Go:0048856) 4882 86 55.48 + 1.55
Developmental Process (Go:0032502) 5199 90 59.08 + 1.52
Cellular Metabolic Process (Go:0044237) 7347 117 83.5 + 1.4
Cellular Process (Go:0009987) 14173 193 161.07 + 1.2
Sensory Perception Of Chemical Stimulus (Go:0007606) 1194 1 13.57 - 0.07
Sensory Perception Of Smell (Go:0007608) 1095 0 12.44 -  < 0.01
Cellular Component No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment
Proteasome Complex (Go:0000502) 70 6 0.8 + 7.54
Endopeptidase Complex (Go:1905369) 71 6 0.81 + 7.44
Peptidase Complex (Go:1905368) 94 7 1.07 + 6.55
Endosome Membrane (Go:0010008) 188 9 2.14 + 4.21
Mitochondrial Protein Complex (Go:0098798) 257 11 2.92 + 3.77
Synapse (Go:0045202) 977 25 11.1 + 2.25
Cytoplasmic Vesicle (Go:0031410) 1779 41 20.22 + 2.03
Intracellular Vesicle (Go:0097708) 1784 41 20.27 + 2.02
Cell Projection (Go:0042995) 2327 52 26.45 + 1.97
Vesicle (Go:0031982) 1914 42 21.75 + 1.93
Plasma Membrane Bounded Cell Projection (Go:0120025) 2142 46 24.34 + 1.89
Mitochondrion (Go:0005739) 1772 37 20.14 + 1.84
Membrane-Bounded Organelle (Go:0043227) 10788 183 122.6 + 1.49
Intracellular Membrane-Bounded Organelle (Go:0043231) 10081 170 114.57 + 1.48
Protein-Containing Complex (Go:0032991) 5241 88 59.56 + 1.48
Cytoplasmic Part (Go:0044444) 8233 136 93.57 + 1.45
Intracellular Organelle (Go:0043229) 11737 192 133.39 + 1.44
Intracellular Organelle Part (Go:0044446) 7029 114 79.88 + 1.43
Organelle (Go:0043226) 11981 194 136.16 + 1.42
Cytoplasm (Go:0005737) 10672 169 121.28 + 1.39
Organelle Part (Go:0044422) 7293 115 82.88 + 1.39
Intracellular Part (Go:0044424) 13409 209 152.39 + 1.37
Intracellular (Go:0005622) 13486 209 153.26 + 1.36
Nucleus (Go:0005634) 6641 102 75.47 + 1.35
Cell Part (Go:0044464) 15775 222 179.28 + 1.24
Cell (Go:0005623) 15778 222 179.31 + 1.24
Reactome Pathways No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment
Metabolism Of Folate And Pterines (R-Mmu-196757) 16 3 0.18 + 16.5
Disassembly Of The Destruction Complex And Recruitment Of Axin To The Membrane (R-Mmu-4641262) 20 3 0.23 + 13.2
Cross-Presentation Of Soluble Exogenous Antigens (Endosomes) (R-Mmu-1236978) 47 6 0.53 + 11.23
Degradation Of Gli1 By The Proteasome (R-Mmu-5610780) 57 7 0.65 + 10.81
Asymmetric Localization Of Pcp Proteins (R-Mmu-4608870) 59 7 0.67 + 10.44
Cdk-Mediated Phosphorylation And Removal Of Cdc6 (R-Mmu-69017) 51 6 0.58 + 10.35
Regulation Of Ornithine Decarboxylase (Odc) (R-Mmu-350562) 51 6 0.58 + 10.35
Ubiquitin-Dependent Degradation Of Cyclin D1 (R-Mmu-69229) 52 6 0.59 + 10.15
Ubiquitin-Dependent Degradation Of Cyclin D (R-Mmu-75815) 52 6 0.59 + 10.15
Autodegradation Of The E3 Ubiquitin Ligase Cop1 (R-Mmu-349425) 52 6 0.59 + 10.15
P53-Independent G1/S Dna Damage Checkpoint (R-Mmu-69613) 53 6 0.6 + 9.96
P53-Independent Dna Damage Response (R-Mmu-69610) 53 6 0.6 + 9.96
Ubiquitin Mediated Degradation Of Phosphorylated Cdc25A (R-Mmu-69601) 53 6 0.6 + 9.96
Stabilization Of P53 (R-Mmu-69541) 55 6 0.63 + 9.6
Degradation Of Axin (R-Mmu-4641257) 55 6 0.63 + 9.6
Scf-Beta-Trcp Mediated Degradation Of Emi1 (R-Mmu-174113) 55 6 0.63 + 9.6
Auf1 (Hnrnp D0) Binds And Destabilizes Mrna (R-Mmu-450408) 55 6 0.63 + 9.6
Degradation Of Dvl (R-Mmu-4641258) 57 6 0.65 + 9.26
Gli3 Is Processed To Gli3R By The Proteasome (R-Mmu-5610785) 58 6 0.66 + 9.1
Nik-->Noncanonical Nf-Kb Signaling (R-Mmu-5676590) 59 6 0.67 + 8.95
Cdt1 Association With The Cdc6:Orc:Origin Complex (R-Mmu-68827) 59 6 0.67 + 8.95
Dectin-1 Mediated Noncanonical Nf-Kb Signaling (R-Mmu-5607761) 59 6 0.67 + 8.95
Scf(Skp2)-Mediated Degradation Of P27/P21 (R-Mmu-187577) 60 6 0.68 + 8.8
The Role Of Gtse1 In G2/M Progression After G2 Checkpoint (R-Mmu-8852276) 60 6 0.68 + 8.8
Pcp/Ce Pathway (R-Mmu-4086400) 82 8 0.93 + 8.58
Hedgehog Ligand Biogenesis (R-Mmu-5358346) 62 6 0.7 + 8.52
Beta-Catenin Independent Wnt Signaling (R-Mmu-3858494) 104 10 1.18 + 8.46
P53-Dependent G1/S Dna Damage Checkpoint (R-Mmu-69580) 63 6 0.72 + 8.38
Autodegradation Of Cdh1 By Cdh1:Apc/C (R-Mmu-174084) 63 6 0.72 + 8.38
P53-Dependent G1 Dna Damage Response (R-Mmu-69563) 63 6 0.72 + 8.38
Degradation Of Beta-Catenin By The Destruction Complex (R-Mmu-195253) 75 7 0.85 + 8.21
G1/S Dna Damage Checkpoints (R-Mmu-69615) 65 6 0.74 + 8.12
Activation Of Nf-Kappab In B Cells (R-Mmu-1169091) 66 6 0.75 + 8
Regulation Of Ras By Gaps (R-Mmu-5658442) 67 6 0.76 + 7.88
Apc/C:Cdc20 Mediated Degradation Of Securin (R-Mmu-174154) 67 6 0.76 + 7.88
Cyclin E Associated Events During G1/S Transition  (R-Mmu-69202) 68 6 0.77 + 7.76
Assembly Of The Pre-Replicative Complex (R-Mmu-68867) 68 6 0.77 + 7.76
Cyclin A:Cdk2-Associated Events At S Phase Entry (R-Mmu-69656) 69 6 0.78 + 7.65
Orc1 Removal From Chromatin (R-Mmu-68949) 71 6 0.81 + 7.44
Switching Of Origins To A Post-Replicative State (R-Mmu-69052) 71 6 0.81 + 7.44
Cdc20:Phospho-Apc/C Mediated Degradation Of Cyclin A (R-Mmu-174184) 72 6 0.82 + 7.33
Apc/C:Cdh1 Mediated Degradation Of Cdc20 And Other Apc/C:Cdh1 Targeted Proteins In Late Mitosis/Early G1 (R-Mmu-174178) 72 6 0.82 + 7.33
Apc:Cdc20 Mediated Degradation Of Cell Cycle Proteins Prior To Satisfation Of The Cell Cycle Checkpoint (R-Mmu-179419) 73 6 0.83 + 7.23
Removal Of Licensing Factors From Origins (R-Mmu-69300) 73 6 0.83 + 7.23
Mapk6/Mapk4 Signaling (R-Mmu-5687128) 74 6 0.84 + 7.13
Apc/C:Cdc20 Mediated Degradation Of Mitotic Proteins (R-Mmu-176409) 75 6 0.85 + 7.04
Activation Of Apc/C And Apc/C:Cdc20 Mediated Degradation Of Mitotic Proteins (R-Mmu-176814) 76 6 0.86 + 6.95
Regulation Of Dna Replication (R-Mmu-69304) 76 6 0.86 + 6.95
Metabolism Of Polyamines (R-Mmu-351202) 80 6 0.91 + 6.6
Fceri Mediated Nf-Kb Activation (R-Mmu-2871837) 80 6 0.91 + 6.6
Regulation Of Apc/C Activators Between G1/S And Early Anaphase (R-Mmu-176408) 82 6 0.93 + 6.44
Hedgehog 'Off' State (R-Mmu-5610787) 110 8 1.25 + 6.4
Regulation Of Mrna Stability By Proteins That Bind Au-Rich Elements (R-Mmu-450531) 83 6 0.94 + 6.36
Dna Replication Pre-Initiation (R-Mmu-69002) 83 6 0.94 + 6.36
M/G1 Transition (R-Mmu-68874) 83 6 0.94 + 6.36
Hedgehog 'On' State (R-Mmu-5632684) 113 8 1.28 + 6.23
Uch Proteinases (R-Mmu-5689603) 86 6 0.98 + 6.14
Regulation Of Mitotic Cell Cycle (R-Mmu-453276) 88 6 1 + 6
Apc/C-Mediated Degradation Of Cell Cycle Proteins (R-Mmu-174143) 88 6 1 + 6
Tcf Dependent Signaling In Response To Wnt (R-Mmu-201681) 147 10 1.67 + 5.99
Downstream Tcr Signaling (R-Mmu-202424) 89 6 1.01 + 5.93
Clec7A (Dectin-1) Signaling (R-Mmu-5607764) 90 6 1.02 + 5.87
Tcr Signaling (R-Mmu-202403) 109 7 1.24 + 5.65
G1/S Transition (R-Mmu-69206) 110 7 1.25 + 5.6
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ACCEPTED MANUSCRIPTAbc-Family Proteins Mediated Transport (R-Mmu-382556) 95 6 1.08 + 5.56
Tnfr2 Non-Canonical Nf-Kb Pathway (R-Mmu-5668541) 95 6 1.08 + 5.56
Antigen Processing-Cross Presentation (R-Mmu-1236975) 95 6 1.08 + 5.56
Synthesis Of Dna (R-Mmu-69239) 98 6 1.11 + 5.39
Dna Replication (R-Mmu-69306) 106 6 1.2 + 4.98
S Phase (R-Mmu-69242) 126 7 1.43 + 4.89
C-Type Lectin Receptors (Clrs) (R-Mmu-5621481) 113 6 1.28 + 4.67
Mitotic G1-G1/S Phases (R-Mmu-453279) 132 7 1.5 + 4.67
Signaling By Hedgehog (R-Mmu-5358351) 153 8 1.74 + 4.6
Signaling By Wnt (R-Mmu-195721) 218 11 2.48 + 4.44
Ub-Specific Processing Proteases (R-Mmu-5689880) 162 8 1.84 + 4.35
G2/M Transition (R-Mmu-69275) 162 8 1.84 + 4.35
Mitotic G2-G2/M Phases (R-Mmu-453274) 164 8 1.86 + 4.29
Metabolism Of Amino Acids And Derivatives (R-Mmu-71291) 217 10 2.47 + 4.05
Axon Guidance (R-Mmu-422475) 435 17 4.94 + 3.44
Developmental Biology (R-Mmu-1266738) 644 18 7.32 + 2.46
Unclassified (Unclassified) 14480 140 164.56 - 0.85
Supplemental Table 4: Gene ontology enrichment analysis of genes downregulated after 4 weeks of Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s exact test with FDR multiple test correction).
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Olfactory Receptor Activity (Go:0004984) 1096 0 15.9 -  < 0.01 1.50E-07 6.82E-04
Protein Domain Specific Binding (Go:0019904) 777 29 11.27 + 2.57 5.58E-06 1.27E-02
Biological Process No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Regulation Of Hormone Secretion (Go:0046883) 288 16 4.18 + 3.83 8.83E-06 2.72E-02
Regulation Of Hormone Levels (Go:0010817) 524 22 7.6 + 2.89 1.43E-05 3.14E-02
Regulation Of Cellular Component Organization (Go:0051128) 2348 61 34.07 + 1.79 1.02E-05 2.63E-02
Regulation Of Biological Quality (Go:0065008) 3583 86 51.99 + 1.65 1.97E-06 7.61E-03
Sensory Perception (Go:0007600) 1576 3 22.87 - 0.13 2.56E-07 1.31E-03
Sensory Perception Of Smell (Go:0007608) 1095 0 15.89 -  < 0.01 1.50E-07 1.15E-03
Sensory Perception Of Chemical Stimulus (Go:0007606) 1194 0 17.32 -  < 0.01 4.58E-08 7.07E-04
Cellular Component No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Postsynaptic Density (Go:0014069) 254 13 3.69 + 3.53 1.34E-04 1.17E-02
Postsynaptic Specialization (Go:0099572) 256 13 3.71 + 3.5 1.44E-04 1.20E-02
Asymmetric Synapse (Go:0032279) 258 13 3.74 + 3.47 1.55E-04 1.24E-02
Neuron To Neuron Synapse (Go:0098984) 262 13 3.8 + 3.42 1.79E-04 1.38E-02
Neuronal Cell Body (Go:0043025) 680 25 9.87 + 2.53 3.20E-05 3.84E-03
Axon (Go:0030424) 664 23 9.63 + 2.39 1.99E-04 1.41E-02
Cell Body (Go:0044297) 761 25 11.04 + 2.26 1.88E-04 1.39E-02
Neuron Part (Go:0097458) 1718 51 24.93 + 2.05 1.70E-06 2.17E-04
Somatodendritic Compartment (Go:0036477) 990 29 14.36 + 2.02 5.81E-04 3.98E-02
Neuron Projection (Go:0043005) 1435 40 20.82 + 1.92 9.42E-05 1.00E-02
Intracellular Organelle Lumen (Go:0070013) 3861 84 56.02 + 1.5 1.13E-04 1.14E-02
Organelle Lumen (Go:0043233) 3866 84 56.09 + 1.5 1.15E-04 1.10E-02
Membrane-Enclosed Lumen (Go:0031974) 3866 84 56.09 + 1.5 1.15E-04 1.05E-02
Intracellular Non-Membrane-Bounded Organelle (Go:0043232) 3971 82 57.62 + 1.42 7.49E-04 4.96E-02
Non-Membrane-Bounded Organelle (Go:0043228) 3971 82 57.62 + 1.42 7.49E-04 4.79E-02
Intracellular Organelle Part (Go:0044446) 7029 145 101.98 + 1.42 6.91E-07 1.02E-04
Intracellular Membrane-Bounded Organelle (Go:0043231) 10081 206 146.27 + 1.41 4.20E-11 1.34E-08
Organelle Part (Go:0044422) 7293 149 105.81 + 1.41 8.63E-07 1.18E-04
Cytoplasmic Part (Go:0044444) 8233 168 119.45 + 1.41 5.60E-08 1.08E-05
Membrane-Bounded Organelle (Go:0043227) 10788 214 156.52 + 1.37 2.26E-10 5.43E-08
Intracellular Organelle (Go:0043229) 11737 232 170.29 + 1.36 4.19E-12 2.68E-09
Cytoplasm (Go:0005737) 10672 210 154.84 + 1.36 1.00E-09 2.14E-07
Organelle (Go:0043226) 11981 235 173.83 + 1.35 5.76E-12 2.76E-09
Nucleus (Go:0005634) 6641 130 96.35 + 1.35 8.47E-05 9.56E-03
Intracellular (Go:0005622) 13486 258 195.67 + 1.32 2.23E-13 4.28E-10
Intracellular Part (Go:0044424) 13409 256 194.55 + 1.32 5.90E-13 5.67E-10
Cell (Go:0005623) 15778 280 228.92 + 1.22 3.25E-11 1.25E-08
Cell Part (Go:0044464) 15775 279 228.88 + 1.22 7.90E-11 2.17E-08
Cellular_Component (Go:0005575) 20724 320 300.69 + 1.06 5.58E-07 9.75E-05
Unclassified (Unclassified) 1538 3 22.31 - 0.13 5.58E-07 8.94E-05
Supplemental Table 5: Gene ontology enrichment analysis of genes upregulated after 2 days of Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation 
function, Fisher’s exact test with FDR multiple test correction).
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Calcium-Dependent Phospholipid Binding (Go:0005544) 50 6 0.69 + 8.65 1.15E-04 4.75E-02
Calcium Ion Binding (Go:0005509) 593 30 8.23 + 3.64 2.77E-09 1.26E-05
Phospholipid Binding (Go:0005543) 399 17 5.54 + 3.07 6.71E-05 3.06E-02
Ion Transmembrane Transporter Activity (Go:0015075) 831 30 11.53 + 2.6 2.99E-06 3.41E-03
Inorganic Molecular Entity Transmembrane Transporter Activity (Go:0015318) 793 28 11.01 + 2.54 9.63E-06 8.79E-03
Transmembrane Transporter Activity (Go:0022857) 1005 31 13.95 + 2.22 4.76E-05 2.72E-02
Transporter Activity (Go:0005215) 1161 34 16.11 + 2.11 5.41E-05 2.74E-02
Anion Binding (Go:0043168) 2631 60 36.52 + 1.64 1.28E-04 4.87E-02
Ion Binding (Go:0043167) 5348 107 74.23 + 1.44 3.09E-05 2.01E-02
Protein Binding (Go:0005515) 8720 158 121.03 + 1.31 2.89E-05 2.20E-02
Binding (Go:0005488) 12812 219 177.83 + 1.23 1.78E-06 2.70E-03
Olfactory Receptor Activity (Go:0004984) 1096 0 15.21 -  < 0.01 3.34E-07 7.61E-04
Biological Process No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Synaptic Vesicle Endocytosis (Go:0048488) 32 5 0.44 + 11.26 1.42E-04 3.83E-02
Synaptic Vesicle Recycling (Go:0036465) 40 6 0.56 + 10.81 3.71E-05 1.79E-02
Cellular Response To Topologically Incorrect Protein (Go:0035967) 81 8 1.12 + 7.12 3.04E-05 1.62E-02
Vesicle Localization (Go:0051648) 178 12 2.47 + 4.86 1.30E-05 8.34E-03
Establishment Of Vesicle Localization (Go:0051650) 168 11 2.33 + 4.72 3.83E-05 1.79E-02
Locomotory Behavior (Go:0007626) 232 12 3.22 + 3.73 1.47E-04 3.91E-02
Proteasomal Protein Catabolic Process (Go:0010498) 289 14 4.01 + 3.49 8.18E-05 2.34E-02
Chemical Synaptic Transmission (Go:0007268) 345 16 4.79 + 3.34 4.23E-05 1.72E-02
Anterograde Trans-Synaptic Signaling (Go:0098916) 345 16 4.79 + 3.34 4.23E-05 1.67E-02
Trans-Synaptic Signaling (Go:0099537) 354 16 4.91 + 3.26 5.66E-05 1.94E-02
Synaptic Signaling (Go:0099536) 356 16 4.94 + 3.24 6.03E-05 1.86E-02
Modulation Of Chemical Synaptic Transmission (Go:0050804) 395 17 5.48 + 3.1 5.96E-05 1.91E-02
Regulation Of Trans-Synaptic Signaling (Go:0099177) 395 17 5.48 + 3.1 5.96E-05 1.88E-02
Positive Regulation Of Nervous System Development (Go:0051962) 603 25 8.37 + 2.99 2.09E-06 2.48E-03
Positive Regulation Of Neurogenesis (Go:0050769) 536 21 7.44 + 2.82 3.11E-05 1.60E-02
Positive Regulation Of Cell Development (Go:0010720) 608 23 8.44 + 2.73 2.21E-05 1.22E-02
Neuron Projection Development (Go:0031175) 661 25 9.17 + 2.72 9.70E-06 7.87E-03
Regulation Of Neuron Projection Development (Go:0010975) 560 21 7.77 + 2.7 5.69E-05 1.87E-02
Regulation Of Nervous System Development (Go:0051960) 972 36 13.49 + 2.67 1.57E-07 6.05E-04
Regulation Of Neurogenesis (Go:0050767) 875 32 12.15 + 2.63 1.05E-06 1.80E-03
Regulation Of Cell Development (Go:0060284) 1003 35 13.92 + 2.51 1.34E-06 1.87E-03
Cell Morphogenesis (Go:0000902) 692 24 9.61 + 2.5 5.57E-05 1.95E-02
Regulation Of Neuron Differentiation (Go:0045664) 724 25 10.05 + 2.49 4.17E-05 1.74E-02
Regulation Of Plasma Membrane Bounded Cell Projection Organization (Go:0120035) 714 24 9.91 + 2.42 1.21E-04 3.39E-02
Neuron Development (Go:0048666) 808 27 11.22 + 2.41 4.34E-05 1.67E-02
Regulation Of Cell Projection Organization (Go:0031344) 723 24 10.04 + 2.39 1.35E-04 3.72E-02
Cellular Component Morphogenesis (Go:0032989) 789 26 10.95 + 2.37 7.25E-05 2.11E-02
Neuron Differentiation (Go:0030182) 981 32 13.62 + 2.35 1.10E-05 8.09E-03
Plasma Membrane Bounded Cell Projection Organization (Go:0120036) 1014 33 14.07 + 2.34 8.24E-06 7.06E-03
Cell Projection Organization (Go:0030030) 1062 34 14.74 + 2.31 1.11E-05 7.80E-03
Neurogenesis (Go:0022008) 1657 53 23 + 2.3 2.46E-08 1.90E-04
Nervous System Development (Go:0007399) 2106 67 29.23 + 2.29 1.75E-10 2.70E-06
Positive Regulation Of Cellular Component Organization (Go:0051130) 1205 38 16.73 + 2.27 3.56E-06 3.43E-03
Generation Of Neurons (Go:0048699) 1561 49 21.67 + 2.26 1.42E-07 7.28E-04
Positive Regulation Of Cell Differentiation (Go:0045597) 1033 32 14.34 + 2.23 3.27E-05 1.63E-02
Ion Transport (Go:0006811) 1103 33 15.31 + 2.16 5.67E-05 1.90E-02
Movement Of Cell Or Subcellular Component (Go:0006928) 1273 36 17.67 + 2.04 6.69E-05 1.99E-02
Cell Development (Go:0048468) 1601 44 22.22 + 1.98 2.05E-05 1.17E-02
Regulation Of Cell Differentiation (Go:0045595) 1758 48 24.4 + 1.97 1.06E-05 8.18E-03
Regulation Of Multicellular Organismal Development (Go:2000026) 1983 52 27.52 + 1.89 1.27E-05 8.49E-03
Regulation Of Cellular Component Organization (Go:0051128) 2348 61 32.59 + 1.87 2.51E-06 2.58E-03
Cellular Localization (Go:0051641) 1921 49 26.66 + 1.84 4.06E-05 1.74E-02
Regulation Of Developmental Process (Go:0050793) 2515 63 34.91 + 1.8 5.07E-06 4.60E-03
Regulation Of Localization (Go:0032879) 2619 62 36.35 + 1.71 3.87E-05 1.76E-02
Transport (Go:0006810) 3380 80 46.91 + 1.71 1.42E-06 1.83E-03
Establishment Of Localization (Go:0051234) 3511 83 48.73 + 1.7 9.19E-07 1.77E-03
Regulation Of Biological Quality (Go:0065008) 3583 84 49.73 + 1.69 1.13E-06 1.75E-03
Regulation Of Multicellular Organismal Process (Go:0051239) 2912 66 40.42 + 1.63 6.16E-05 1.86E-02
Localization (Go:0051179) 4587 103 63.67 + 1.62 2.84E-07 7.29E-04
System Development (Go:0048731) 4022 90 55.83 + 1.61 2.43E-06 2.68E-03
Cellular Developmental Process (Go:0048869) 3589 80 49.82 + 1.61 1.66E-05 9.84E-03
Cell Differentiation (Go:0030154) 3506 77 48.66 + 1.58 3.99E-05 1.76E-02
Cellular Component Organization Or Biogenesis (Go:0071840) 5061 111 70.25 + 1.58 1.80E-07 5.56E-04
Cellular Component Organization (Go:0016043) 4876 106 67.68 + 1.57 7.59E-07 1.67E-03
Multicellular Organism Development (Go:0007275) 4585 94 63.64 + 1.48 5.17E-05 1.85E-02
Developmental Process (Go:0032502) 5199 104 72.16 + 1.44 4.62E-05 1.74E-02
Sensory Perception Of Smell (Go:0007608) 1095 2 15.2 - 0.13 4.70E-05 1.73E-02
Sensory Perception Of Chemical Stimulus (Go:0007606) 1194 2 16.57 - 0.12 1.57E-05 9.70E-03
Cellular Component No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Noc4P-Nop14P Complex (Go:0030692) 2 2 0.03 + 72.05 1.10E-03 3.58E-02
Axon Cytoplasm (Go:1904115) 14 3 0.19 + 15.44 1.50E-03 4.50E-02
Gaba Receptor Complex (Go:1902710) 19 4 0.26 + 15.17 2.48E-04 1.08E-02
Inhibitory Synapse (Go:0060077) 22 4 0.31 + 13.1 4.06E-04 1.56E-02
Exocytic Vesicle Membrane (Go:0099501) 82 8 1.14 + 7.03 3.30E-05 2.05E-03
Synaptic Vesicle Membrane (Go:0030672) 82 8 1.14 + 7.03 3.30E-05 1.98E-03
Synaptic Vesicle (Go:0008021) 190 14 2.64 + 5.31 9.26E-07 9.35E-05
Exocytic Vesicle (Go:0070382) 205 15 2.85 + 5.27 4.10E-07 4.37E-05
Transport Vesicle Membrane (Go:0030658) 115 8 1.6 + 5.01 2.97E-04 1.27E-02
Terminal Bouton (Go:0043195) 120 8 1.67 + 4.8 3.89E-04 1.53E-02
Transport Vesicle (Go:0030133) 284 18 3.94 + 4.57 2.14E-07 3.16E-05
Presynapse (Go:0098793) 389 23 5.4 + 4.26 1.45E-08 2.79E-06
Neuron Projection Terminus (Go:0044306) 211 12 2.93 + 4.1 6.27E-05 3.01E-03
Axon Terminus (Go:0043679) 194 11 2.69 + 4.09 1.29E-04 5.78E-03
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ACCEPTED MANUSCRIPTLeading Edge Membrane (Go:0031256) 145 8 2.01 + 3.97 1.26E-03 4.02E-02
Axon (Go:0030424) 664 33 9.22 + 3.58 6.49E-10 1.38E-07
Synapse Part (Go:0044456) 787 38 10.92 + 3.48 6.51E-11 3.13E-08
Axon Part (Go:0033267) 439 21 6.09 + 3.45 1.70E-06 1.55E-04
Postsynaptic Membrane (Go:0045211) 261 12 3.62 + 3.31 4.11E-04 1.55E-02
Distal Axon (Go:0150034) 361 16 5.01 + 3.19 7.06E-05 3.30E-03
Synapse (Go:0045202) 977 42 13.56 + 3.1 1.87E-10 7.20E-08
Postsynapse (Go:0098794) 500 21 6.94 + 3.03 1.16E-05 9.26E-04
Neuron Projection (Go:0043005) 1435 60 19.92 + 3.01 3.71E-14 3.56E-11
Synaptic Membrane (Go:0097060) 336 14 4.66 + 3 3.62E-04 1.45E-02
Cytoplasmic Vesicle Membrane (Go:0030659) 292 12 4.05 + 2.96 1.05E-03 3.49E-02
Neuron Part (Go:0097458) 1718 69 23.85 + 2.89 1.96E-15 3.76E-12
Neuronal Cell Body (Go:0043025) 680 24 9.44 + 2.54 4.27E-05 2.35E-03
Cytoplasmic Vesicle Part (Go:0044433) 507 17 7.04 + 2.42 9.70E-04 3.38E-02
Cell Body (Go:0044297) 761 25 10.56 + 2.37 1.06E-04 4.85E-03
Secretory Vesicle (Go:0099503) 551 18 7.65 + 2.35 1.28E-03 4.02E-02
Cell Projection (Go:0042995) 2327 74 32.3 + 2.29 1.94E-11 1.24E-08
Plasma Membrane Bounded Cell Projection (Go:0120025) 2142 68 29.73 + 2.29 2.09E-10 6.70E-08
Cell Projection Part (Go:0044463) 1482 47 20.57 + 2.28 2.49E-07 3.19E-05
Plasma Membrane Bounded Cell Projection Part (Go:0120038) 1482 47 20.57 + 2.28 2.49E-07 2.99E-05
Somatodendritic Compartment (Go:0036477) 990 31 13.74 + 2.26 3.96E-05 2.23E-03
Whole Membrane (Go:0098805) 1072 33 14.88 + 2.22 2.63E-05 1.74E-03
Cell Junction (Go:0030054) 1094 33 15.18 + 2.17 5.29E-05 2.82E-03
Plasma Membrane Region (Go:0098590) 1034 28 14.35 + 1.95 9.70E-04 3.32E-02
Bounding Membrane Of Organelle (Go:0098588) 1028 27 14.27 + 1.89 1.67E-03 4.92E-02
Cytoplasmic Vesicle (Go:0031410) 1779 46 24.69 + 1.86 5.34E-05 2.77E-03
Intracellular Vesicle (Go:0097708) 1784 46 24.76 + 1.86 5.56E-05 2.81E-03
Integral Component Of Plasma Membrane (Go:0005887) 1363 35 18.92 + 1.85 5.12E-04 1.89E-02
Vesicle (Go:0031982) 1914 49 26.57 + 1.84 3.85E-05 2.24E-03
Intrinsic Component Of Plasma Membrane (Go:0031226) 1432 36 19.88 + 1.81 6.66E-04 2.37E-02
Endomembrane System (Go:0012505) 3721 85 51.65 + 1.65 2.47E-06 2.15E-04
Cell Periphery (Go:0071944) 5171 108 71.77 + 1.5 3.67E-06 3.06E-04
Plasma Membrane (Go:0005886) 5041 103 69.97 + 1.47 2.07E-05 1.47E-03
Intrinsic Component Of Membrane (Go:0031224) 5932 115 82.34 + 1.4 5.63E-05 2.77E-03
Cytoplasmic Part (Go:0044444) 8233 159 114.28 + 1.39 2.92E-07 3.30E-05
Membrane Part (Go:0044425) 7198 137 99.91 + 1.37 1.29E-05 9.91E-04
Integral Component Of Membrane (Go:0016021) 5774 108 80.14 + 1.35 5.20E-04 1.89E-02
Membrane (Go:0016020) 9219 171 127.96 + 1.34 1.22E-06 1.17E-04
Intracellular Organelle Part (Go:0044446) 7029 128 97.56 + 1.31 3.40E-04 1.39E-02
Cytoplasm (Go:0005737) 10672 194 148.13 + 1.31 2.11E-07 3.38E-05
Organelle Part (Go:0044422) 7293 132 101.23 + 1.3 3.08E-04 1.29E-02
Membrane-Bounded Organelle (Go:0043227) 10788 188 149.74 + 1.26 1.60E-05 1.18E-03
Intracellular Part (Go:0044424) 13409 230 186.12 + 1.24 2.16E-07 2.96E-05
Intracellular (Go:0005622) 13486 231 187.19 + 1.23 2.08E-07 3.63E-05
Intracellular Organelle (Go:0043229) 11737 200 162.91 + 1.23 2.61E-05 1.79E-03
Organelle (Go:0043226) 11981 203 166.3 + 1.22 3.25E-05 2.08E-03
Cell Part (Go:0044464) 15775 266 218.96 + 1.21 5.66E-10 1.36E-07
Cell (Go:0005623) 15778 266 219 + 1.21 5.66E-10 1.55E-07
Intracellular Membrane-Bounded Organelle (Go:0043231) 10081 169 139.93 + 1.21 1.03E-03 3.46E-02
Cellular_Component (Go:0005575) 20724 301 287.65 + 1.05 1.36E-03 4.20E-02
Unclassified (Unclassified) 1538 8 21.35 - 0.37 1.36E-03 4.13E-02
Reactome Pathways No. (22262) No.Gene List (323) Expected Over/Under Fold Enrichment Raw P Value FDR
Transmission Across Chemical Synapses (R-Mmu-112315) 194 13 2.69 + 4.83 6.03E-06 4.56E-03
Neuronal System (R-Mmu-112316) 307 18 4.26 + 4.22 6.28E-07 9.50E-04
Transmembrane Transport Of Small Molecules (R-Mmu-382551) 601 23 8.34 + 2.76 1.86E-05 9.37E-03
Supplemental Table 6: Gene ontology enrichment analysis of genes downregulated after 2 days of Cort treatment. (Panther, http://pantherdb.org/; statistical overrepresentation function, Fisher’s exact 
test with FDR multiple test correction).
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ACCEPTED MANUSCRIPTUpstream Regulator Expr Log Ratio Molecule Type Predicted Activation State Activation Z-Score Overlap P-value FDR Target molecules in dataset
HNRNPA2B1 0.035 Other   4.76E-05 5.13E-02
ATG12,CP,CTSV,DNER,FN1,JUP,LPAR1,MAST4,PDE1A,PGM2L1,PPARGC1A,SLC1A2,STK32B,UTRN,V
CAN
miR-22-3p (miRNAs w/seed AGCUGCC)  Mature MicroRNA  0 5.67E-05 5.13E-02 ARRB1,FRAT2,MVB12B,POGK,ZCCHC14,ZNF618
TP53 -0.05 Transcription Regulator  -0.322 2.71E-04 1.64E-01
A2M,ABCA2,ACSS1,ACTN4,AHSA1,AK1,AK4,ARHGEF2,ARRB1,ATP5MC1,CCND3,COL4A1,CP,Cyb5r3
,DAPK1,DDX5,DHFR,DLAT,DNAJC11,DNAJC12,DPYSL4,EDNRA,ENPP2,ESR1,FGF2,FN1,GPR12,GSK3A
,GSTP1,HDAC9,HOMEZ,IGF1,ITGB5,KDR,LPIN1,MAPRE3,MCL1,ME2,MRPL16,Mt2,NAB1,NAMPT,N
COR2,NEXN,NFS1,NPFFR2,PFKFB3,PFKP,PMS2,PPARGC1A,PRKAR2A,PRKG1,PSEN1,PSMA1,PTGS1,P
TN,RBBP4,RYR2,SERPINA3,SESN1,SLC5A3,SMC3,SMURF1,SPHK2,SQLE,SULF2,TET2,TGFB3,TMED7,T
TN,TXN2,VCAN,VIM,ZNF24
mir-183  MicroRNA  -0.094 3.85E-04 1.68E-01 FN1,ITGB1,JUP,SLC30A7,VIM
HSF1 0.492 Transcription Regulator  -0.288 4.93E-04 1.68E-01
AHSA1,CFLAR,DNAJB1,HERC4,HSF2,ITGB5,JARID2,LSM2,MCL1,NCOR1,NCOR2,PMS2,SLC5A3,SPHK
2,VCAN
MFGE8 -0.402 Other   5.58E-04 1.68E-01 CCND3,EDIL3,FGF2
SLC25A33 -0.66 Transporter   9.65E-04 1.98E-01 GABPA,PPARGC1A
KCNJ6 0.777 Ion Channel   9.65E-04 1.98E-01 KCNJ10,KCNJ3
FEV  Transcription Regulator   9.97E-04 1.98E-01 GABRQ,GRIA4,ITGB1,KCTD20,LPAR1,NPY,NR3C1,SATB1,VIM
CTSS 0.484 Peptidase   1.09E-03 1.98E-01 COL4A1,CTSV,CX3CL1,ITGB1,UTRN
LILRB1  Transmembrane Receptor  0 1.25E-03 1.98E-01 FGFR3,ITGB1,MAF,ST3GAL6
TGFB2 0.489 Growth Factor  1.276 1.31E-03 1.98E-01 CFLAR,DOCK4,FN1,KDR,VCAN
TCOF1 -0.712 Transporter   1.59E-03 2.07E-01 ACVR2A,AK4,ANKRD10,ARIH1,ASAP1,DNAJC11,MED1,PPIL4
FOXO3 -0.551 Transcription Regulator  1.798 1.60E-03 2.07E-01 ATG12,COL4A1,ESR1,FLNB,FN1,Mt1,Mt2,NAMPT,PPARGC1A,PTGS1,PTPRB,SESN1,VIM
mir-96  MicroRNA  -1 2.00E-03 2.30E-01 FN1,JUP,SLC30A7,VIM
APP -0.176 Other   2.35E-03 2.30E-01
AK1,ALDOC,AMPH,ARF4,ATP6V1E1,CFL2,ENPP2,ESR1,FGF2,GNG2,GSTP1,IGF1,INA,MBP,MEF2C,M
ERTK,Mt1,NPY,NR3C1,PACS2,PFKFB3,SLC11A2,SLC1A2,SLC7A11
TGFB1 -0.055 Growth Factor  -0.419 2.36E-03 2.30E-01
ABL1,ACSS1,ARHGEF2,CCND3,CDH11,CELSR2,COL4A1,CX3CR1,DAAM1,DOCK4,EDNRA,FAM107A,F
GF2,FN1,FZD1,GNG2,GPR12,HNRNPAB,IGF1,ITGB1,JUP,KDR,KLF15,LAMC1,LPAR4,PTGS1,RASL11B,
RORA,SERPINA3,SLC1A2,TGFB3,VCAN,VIM
PGR 0.213 Ligand-Dependent Nuclear Receptor  0.269 2.46E-03 2.30E-01 AK4,CCND3,EDNRA,ESR1,FLOT2,FN1,ITGB1,KLF11,KLF5,PFKP,SRSF7,TGFB3,VCAN
MSTN  Growth Factor  0.243 2.49E-03 2.30E-01 CTSV,FN1,IGF1,PPARGC1A,VIM
PTN -0.773 Growth Factor   2.83E-03 2.30E-01 DLK1,MBP
ZNF335 -0.034 Transcription Regulator   2.83E-03 2.30E-01 MEF2C,REST
CASP8AP2 -0.003 Transcription Regulator   2.83E-03 2.30E-01 CFLAR,MCL1
FGF2 0.821 Growth Factor  1.387 3.03E-03 2.30E-01 CCND3,CDH11,EFNB2,FGF2,FGFR3,FN1,GCH1,HRH3,ITGB1,LEF1,NPY,VIM
FZD8 0.398 G-Protein Coupled Receptor   3.05E-03 2.30E-01 FN1,VCAN,VIM
miR-16-5p (and other miRNAs w/seed AGCAGCA)  Mature MicroRNA Inhibited -2.183 3.30E-03 2.39E-01 CCND3,FGF2,GALNT13,IGF1,MGAT4A
VEGFA 0.18 Growth Factor  1.299 3.56E-03 2.39E-01 ADAM15,CTSV,EFNB2,FGF2,FN1,ITGB1,KDR,MCL1,PPARGC1A,TRPC6
mir-182  MicroRNA  -1.633 3.57E-03 2.39E-01 ADCY6,CDH4,FN1,JUP,SLC30A7,VIM
MKNK1 -0.574 Kinase  -1.667 3.70E-03 2.39E-01 ACOT7,ARIH1,ARVCF,CP,FLNB,HSD17B4,LAMC1,TMBIM6,VIM
LOXL2  Enzyme   4.09E-03 2.39E-01 ESR1,FN1,VIM
LMO4 0.343 Transcription Regulator   4.09E-03 2.39E-01 CUL3,PPARGC1A,RYR2
IFRD1 -0.071 Other   4.09E-03 2.39E-01 IGF1,LAMA2,MTTP
TSC2 -0.017 Other  -0.707 4.80E-03 2.72E-01 A2M,CCND3,CP,FAM107A,MCL1,Mt1,PGM2L1,PRELP,PSMA1,TMEM176B
GFAP 0.351 Other   5.33E-03 2.93E-01 ITGB1,KCNJ10,SLC1A2
WNT5B  Other   5.55E-03 2.96E-01 FN1,VCAN
mir-22  MicroRNA   6.77E-03 3.28E-01 ARRB1,ESR1,FRAT2
ATP7B 0.428 Transporter  -1 6.87E-03 3.28E-01 CP,LPIN1,Mt1,Mt2,SQLE
CALR -0.057 Transcription Regulator  0.277 6.96E-03 3.28E-01 Calm1 (includes others),FN1,MEF2C,RYR2
POSTN  Other   6.96E-03 3.28E-01 DLK1,MEF2C,PTN,VIM
IKBKG 0.398 Kinase  0.67 7.07E-03 3.28E-01 CP,CX3CL1,ENPP2,GCH1,KLF5,Mt1,Mt2,RYR2,TMEM176B,Ttf1
DNMT3B 0.23 Enzyme  1.108 7.30E-03 3.31E-01 CNR1,DNAJB1,EDNRA,ESR1,FGF2,HDAC9,KDR,MAPRE3,PNPLA3,RECK,RYR2
FOXC2  Transcription Regulator  0.156 7.65E-03 3.31E-01 EFNB2,FN1,LEF1,PPARGC1A,VIM
LGALS3  Other  -0.896 8.08E-03 3.31E-01 COL4A1,CTSV,ENPP2,FN1,IGF1,ITGB1,PPARGC1A
mir-322  MicroRNA   8.43E-03 3.31E-01 FGF2,FN1,VIM
ARG1 0.229 Enzyme   8.43E-03 3.31E-01 CCND3,GSK3A,IGF1
INHBA -0.143 Growth Factor  1.105 8.70E-03 3.31E-01 EFNB2,ESR1,IGF1,KCMF1,MAF,MCL1,PGM2L1,POGZ,SLC1A2,STRBP
NME3  Kinase   9.06E-03 3.31E-01 ITGB1,VIM
GHSR 0.569 G-Protein Coupled Receptor   9.06E-03 3.31E-01 IGF1,NPY
HEPH 0.622 Transporter   9.06E-03 3.31E-01 CNTNAP1,CP
OTUB1  Enzyme   9.06E-03 3.31E-01 ESR1,GREB1
EIF2AK4 -0.754 Kinase   9.20E-03 3.31E-01 CCND3,MBP,PSEN1,PSPH
NRG1  Growth Factor  -0.083 9.41E-03 3.31E-01 FN1,MAF,SLC4A7,UTRN,VIM
MECP2 0.183 Transcription Regulator   9.50E-03 3.31E-01 ESR1,GSTP1,INA,MBP,REST,UBE3A,VIM,YWHAB
Foxp1 0.085 Transcription Regulator  -1.387 1.04E-02 3.46E-01 CNR1,DNER,HCN1,NGEF,PPARGC1A
NFE2L1 -0.11 Transcription Regulator Inhibited -2 1.05E-02 3.46E-01 GSTP1,PSMA1,PSMA7,PSMD11
EGF -0.171 Growth Factor  0.329 1.14E-02 3.46E-01 CDH11,CFLAR,GSTP1,IGF1,MCL1,PTGS1,SERPINA3,SLC4A7,VIM
INSR 0.035 Kinase  -1.664 1.18E-02 3.46E-01
ACTN4,ARHGEF2,ATP5MC1,ATP5MF,Calm1 (includes 
others),CTSV,DLK1,ETFB,Foxn3,GCH1,HSD17B4,IGF1,ITGB5,MED1,NAMPT,NDUFB9,PPARGC1A,SAT
B1,SQLE,TGFB3,WBP1
FLNA -0.224 Other   1.24E-02 3.46E-01 HCN1,ITGB1,LAMC1
MC4R 0.247 G-Protein Coupled Receptor   1.24E-02 3.46E-01 MTTP,NPY,PSMA1
BRD7 -0.099 Transcription Regulator   1.24E-02 3.46E-01 ESR1,FGF2,VCAN
RTN4 0.159 Other  -1 1.25E-02 3.46E-01 GNG2,INA,MAPRE3,MBP,YWHAB
KLF17  Transcription Regulator   1.33E-02 3.46E-01 FN1,VIM
HSP90AA1 0.385 Enzyme   1.33E-02 3.46E-01 CFLAR,FN1
mir-192  MicroRNA   1.33E-02 3.46E-01 FN1,IGF1
mir-205  MicroRNA   1.33E-02 3.46E-01 MED1,VIM
VEGFC -0.169 Growth Factor   1.33E-02 3.46E-01 ITGB1,KDR
NET1 0.192 Other   1.33E-02 3.46E-01 FN1,ITGB1
RB1 0.487 Transcription Regulator  -0.053 1.39E-02 3.46E-01
CCND3,DHFR,DLAT,DLK1,DNAJC11,EDNRA,FGF2,GPR12,IGF1,KDR,MAF,MEF2C,MRPL11,MYL6B,NP
FFR2,PPARGC1A,PTGS1,TXN2
CHUK -0.251 Kinase  0.447 1.40E-02 3.46E-01 ACKR3,CP,CX3CL1,ENPP2,GCH1,KLF5,Mt1,Mt2,NUMB,TMEM176B
MYOC -0.422 Other  -1.432 1.47E-02 3.46E-01 CDH11,FN1,ITGB1,LAMA2,LAMC1,MBP,SLC7A11
GSK3A 0.985 Kinase   1.47E-02 3.46E-01 CFLAR,GSK3A,KDR
Calmodulin  Group  -0.277 1.50E-02 3.46E-01 Calm1 (includes others),KDR,KLF5,NECAB1,TIAM2
PLK1  Kinase   1.50E-02 3.46E-01 ACKR3,CFLAR,EEF1E1,ESR1
DMD 0.096 Other   1.68E-02 3.46E-01 CFL2,CSRNP3,GIGYF2,IGF1,LPIN1,MAP7,Marcks,MEF2C,MLLT3,PPARGC1A,ST3GAL6,UTRN,VIM
PDGF-AA  Complex   1.83E-02 3.46E-01 IGF1,VIM
SENP7 0.709 Peptidase   1.83E-02 3.46E-01 DHFR,VIM
FNIP1 0.203 Other   1.83E-02 3.46E-01 PPARGC1A,ZBTB16
PLCG1 0.017 Enzyme   1.83E-02 3.46E-01 CCND3,KDR
AGTR1 1.243 G-Protein Coupled Receptor   1.85E-02 3.46E-01 CP,FN1,GSTP1,TGFB3
PRDM5 -0.56 Transcription Regulator   1.86E-02 3.46E-01 CDH4,EDNRA,EVL,FBXO33,GABPA,NREP,TCEANC
RICTOR -0.065 Other Activated 2.359 1.86E-02 3.46E-01
ATP5MC1,ATP5MF,ATP6V0E2,ATP6V1E1,CFLAR,MCL1,NDUFB9,PSMA1,PSMA7,PSMD11,PSMD7,P
SME1,PSME2,PSMF1,RPL21
IL1B 0.157 Cytokine  0.465 1.90E-02 3.46E-01
A2M,CRHR1,FGF2,FGFR3,GCH1,IGF1,ITGB1,KDR,MCL1,Mt1,Mt2,PPARGC1A,PSEN1,PTGS1,RORA,S
ERPINA3,SESN1,SLC1A2,SLC7A11,VCAN,VIM
mir-181  MicroRNA   2.00E-02 3.46E-01 MCL1,NLK,SPTLC1
COLQ  Other   2.02E-02 3.46E-01 COL4A1,FN1,PRELP,SGCD,TGFB3,VCAN
SOX4 1.27 Transcription Regulator  -1.033 2.05E-02 3.46E-01 EVL,FN1,IGF1,MBP,Mt1,PLEKHA1,TMEM176B,VIM
CYR61 0.186 Other  1 2.05E-02 3.46E-01 FN1,ITGB1,KDR,NLK
Vegf  Group  -0.708 2.16E-02 3.46E-01 ADAM15,CRTAC1,KDR,LEF1,Mt2,PABPN1
CYB5R4 0.131 Enzyme   2.30E-02 3.46E-01 Mt1,Mt2,PPARGC1A
AChR  Complex   2.30E-02 3.46E-01 ALDOC,SERPINA3,VPS4A
miR-27a-3p (and other miRNAs w/seed UCACAGU)  Mature MicroRNA   2.30E-02 3.46E-01 EFNB2,IGF1,MEF2C
PRKN  Enzyme   2.30E-02 3.46E-01 KDR,MCL1,SEPT4
HDAC1 -0.459 Transcription Regulator  -0.64 2.37E-02 3.46E-01 DHFR,ESR1,FAM107A,GSTP1,INA,MEF2C,PFKFB3,PPARGC1A,REST,RGS10,SATB1,SLC35D1
Pdgfr  Group   2.39E-02 3.46E-01 FN1,VIM
ZNF148 0.346 Transcription Regulator   2.39E-02 3.46E-01 FN1,VIM
GAL3ST1 -0.101 Enzyme   2.39E-02 3.46E-01 ITGB1,MBP
EIF2S1 0.016 Translation Regulator   2.39E-02 3.46E-01 CFLAR,MCL1
SMN1/SMN2 0.931 Other   2.39E-02 3.46E-01 IGF1,UTRN
RNF31 -0.175 Enzyme   2.62E-02 3.46E-01 ESR1,GREB1,TGFB3
CST5  Other  0.775 2.64E-02 3.46E-01
ARHGAP29,ARHGEF2,DHX38,DTNB,FER,HS2ST1,LAMC1,MEF2C,NR3C1,PABPN1,PIP4K2A,SLC7A11,
SNF8,VCAN,VIM
BRD4  Kinase  0 2.72E-02 3.46E-01 COL4A1,FN1,ITGB1,ITGB5,JARID2,KCNA3,KCNQ5,MCL1
CDK4 -0.471 Kinase   2.98E-02 3.46E-01 ARMCX1,CPEB1,DHFR,ENPP2,KLHL24,MBLAC2,MORC4,SATB1,UTRN
MEG3  Other   3.00E-02 3.46E-01 FN1,VIM
MSI2 0.43 Other   3.00E-02 3.46E-01 FN1,NUMB
TENM1 0.331 Transmembrane Receptor   3.00E-02 3.46E-01 SLC1A4,SOX5
RLIM 0.061 Enzyme   3.00E-02 3.46E-01 FN1,VIM
MCAM 0.284 Other   3.00E-02 3.46E-01 FN1,VIM
DEK 0.092 Transcription Regulator   3.00E-02 3.46E-01 LEF1,MCL1
CD44 0.86 Other  -0.233 3.03E-02 3.46E-01 ABCA2,ACKR3,CX3CL1,CX3CR1,Cyb5r3,FN1,LAMC1,MCL1,NECAP2,STAT2,VIM
Becn2  Other   3.11E-02 3.46E-01 CNR1
GÎ±12/13  Group   3.11E-02 3.46E-01 IGF1
INSC 0.062 Other   3.11E-02 3.46E-01 KDR
DNAJ  Group   3.11E-02 3.46E-01 ENPP2
Snord116  Other   3.11E-02 3.46E-01 IGF1
Tug1  Other   3.11E-02 3.46E-01 PPARGC1A
NUDT6 -0.265 Enzyme   3.11E-02 3.46E-01 FGF2
MELK  Kinase   3.11E-02 3.46E-01 MCL1
LPIN2 -0.501 Phosphatase   3.11E-02 3.46E-01 LPIN1
FENDRR  Other   3.11E-02 3.46E-01 FN1
SLC17A7 -0.288 Transporter   3.11E-02 3.46E-01 SLC1A2
SLC39A14 -0.648 Transporter   3.11E-02 3.46E-01 IGF1
SNHG7  Other   3.11E-02 3.46E-01 FAIM2
ARHGAP35 0.058 Transcription Regulator   3.11E-02 3.46E-01 KDR
API5 0.358 Other   3.11E-02 3.46E-01 FGF2
VPS36 -0.461 Other   3.11E-02 3.46E-01 ESR1
SP6  Transcription Regulator   3.11E-02 3.46E-01 LEF1
RNF138 0.262 Enzyme   3.11E-02 3.46E-01 CACNA1A
CYTL1  Cytokine   3.11E-02 3.46E-01 IGF1
Gata  Group   3.11E-02 3.46E-01 KDR
TPH2  Enzyme   3.11E-02 3.46E-01 IGF1
VANGL2 0.239 Other   3.11E-02 3.46E-01 PRICKLE2
DHODH -0.292 Enzyme   3.11E-02 3.46E-01 CFLAR
Igf  Group   3.11E-02 3.46E-01 FN1
BFAR 1.447 Enzyme   3.11E-02 3.46E-01 TMBIM6
ACBD3 -0.257 Other   3.11E-02 3.46E-01 SLC11A2
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OSTN  Other   3.11E-02 3.46E-01 PPARGC1A
SRSF9 -0.997 Enzyme   3.11E-02 3.46E-01 NR3C1
EHD1 0.066 Other   3.11E-02 3.46E-01 ITGB1
COL3A1 -0.126 Other   3.11E-02 3.46E-01 FN1
PMAIP1  Other   3.11E-02 3.46E-01 MCL1
AFAP1 0.359 Other   3.11E-02 3.46E-01 ITGB1
MYOF -0.216 Other   3.11E-02 3.46E-01 KDR
LINC00853  Other   3.11E-02 3.46E-01 CMPK1
PSMA1 -1.152 Peptidase   3.11E-02 3.46E-01 GSTP1
SSPN 0.489 Other   3.11E-02 3.46E-01 UTRN
GPRASP1 0.067 Transporter   3.11E-02 3.46E-01 CNR1
ETF1 0.513 Translation Regulator   3.11E-02 3.46E-01 UTRN
PTS -0.023 Enzyme   3.11E-02 3.46E-01 IGF1
ASH2L -0.144 Transcription Regulator   3.11E-02 3.46E-01 ESR1
PLPP3 -0.054 Phosphatase   3.11E-02 3.46E-01 FN1
ARSA 1.131 Enzyme   3.11E-02 3.46E-01 MBP
KIF11 0.323 Other   3.11E-02 3.46E-01 CFLAR
HOXA4  Transcription Regulator   3.11E-02 3.46E-01 ITGB1
Ikzf1  Transcription Regulator   3.11E-02 3.46E-01 FGFR3
SRRM4 -0.093 Other   3.11E-02 3.46E-01 REST
VPS18 -0.716 Transporter   3.11E-02 3.46E-01 ITGB1
ITGA7 0.193 Other   3.11E-02 3.46E-01 ITGB1
RPN2 0.415 Enzyme   3.11E-02 3.46E-01 GSTP1
ERCC6 0.362 Transcription Regulator   3.11E-02 3.46E-01 MBP
CDO1 0.097 Enzyme   3.11E-02 3.46E-01 IGF1
RANBP2  Enzyme   3.11E-02 3.46E-01 FN1
CXXC4 0.53 Other   3.11E-02 3.46E-01 TET2
UBE2D2 1.118 Enzyme   3.11E-02 3.46E-01 ESR1
protein phosphatase  Complex   3.11E-02 3.46E-01 ESR1
DNMT3A -0.166 Enzyme  0.816 3.24E-02 3.58E-01 CNR1,EDNRA,FGF2,GRIA4,Mt1,PDE1A,PTGS1,RYR2
FAM3B  Cytokine   3.34E-02 3.60E-01 FN1,MED1,PTN
ALDH2 0.543 Enzyme   3.34E-02 3.60E-01 PSPH,SLC1A4,SLC7A11
COL4A3 0.038 Other   3.34E-02 3.60E-01 COL4A1,FN1,LAMC1
CTBP1 -0.492 Enzyme   3.34E-02 3.60E-01 ACKR3,ENPP2,JUP
REL 0.261 Transcription Regulator  0 3.38E-02 3.60E-01 ARHGEF11,CMPK1,COPS4,CTSV,DHFR,ESR1,FN1,JUP,KDR,MLLT3,VIM,ZHX3
EP300 0.04 Transcription Regulator   3.38E-02 3.60E-01
CCND3,CFLAR,CLOCK,EVL,FN1,GNG2,GREB1,IGF1,JUP,MAF,MEF2C,NR3C1,PLEKHA1,PPARGC1A,SL
C7A11,UTRN
DYSF -0.053 Other   3.44E-02 3.65E-01 ARPC2,CTSV,DNAJB1,FN1,ITGB1,SERPINA3
IKBKB -0.015 Kinase  0.92 3.47E-02 3.66E-01 CFLAR,CP,CX3CL1,ENPP2,GCH1,ITGB5,KLF5,MBP,Mt1,Mt2,SMURF1,TMEM176B,VCAN
WISP2  Growth Factor  1 3.50E-02 3.66E-01 ESR1,FN1,JUP,VIM
miR-100-5p (and other miRNAs w/seed ACCCGUA)  Mature MicroRNA   3.68E-02 3.77E-01 CCND3,FGFR3
MAFG 0.689 Transcription Regulator   3.68E-02 3.77E-01 GLRA1,GSTP1
ITGA2 -0.012 Transmembrane Receptor   3.68E-02 3.77E-01 IGF1,ITGB1
RCOR2 0.331 Transcription Regulator   3.68E-02 3.77E-01 INA,REST
PTEN 0.218 Phosphatase  -1.607 3.73E-02 3.77E-01
ARF4,CTSV,CX3CR1,DLAT,EFNB2,ESR1,FGFR3,GPR12,KDR,MBP,MCL1,NPFFR2,PFKFB3,PPARGC1A,P
TGS1,PTN
TAF4B -0.943 Transcription Regulator   3.73E-02 3.77E-01 FN1,TGFB3,ZBTB16
IL6  Cytokine  1.51 3.82E-02 3.83E-01
A2M,ACVR2A,ENPP2,FN1,GATAD2A,GCH1,HRH3,IGF1,ITGB1,ITGB5,MAF,MCL1,MERTK,Mt1,NAMP
T,RORA,SERPINA3,WARS
FOXO4 -0.397 Transcription Regulator   3.83E-02 3.83E-01 COL4A1,FLNB,NAMPT,PSMD11,PTGS1,PTPRB
CNTF -0.435 Cytokine  -0.927 4.08E-02 4.01E-01 CNR1,ENPP2,FGF2,VIM
DLL4  Other   4.14E-02 4.01E-01 EFNB2,KDR,MAF
E2F1  Transcription Regulator  -0.245 4.15E-02 4.01E-01
ATG12,ATP5MC1,Calm1 (includes 
others),CCND3,CFLAR,DCC,DHFR,GABARAP,IGF1,KCNA3,KDR,MAF,MCL1,MTHFD1,PPARGC1A,RBB
P4,UHRF2
SOD1 -0.025 Enzyme   4.17E-02 4.01E-01 ALDOC,CNR1,CP,DCC,GRIA4,GSTP1,IGF1,Mt1,Mt2,NPY,SLC11A2,SLC1A2
S100A9  Other  -0.333 4.19E-02 4.01E-01 A2M,ACSS1,CP,DYRK3,ENPP2,HTR4,IGF1,KLF15,VCAN
CG  Complex  0.841 4.25E-02 4.01E-01
CCND3,CTSV,EFNB2,ENPP2,FZD1,IGF1,ITGB1,ITGB5,KCNJ3,KCNQ5,KCNT2,MAF,MCL1,PFKFB3,PTG
S1,RORA,VCAN
HBA1/HBA2  Transporter  -1 4.39E-02 4.01E-01 ATP5MC1,ATP5MF,Mt1,NDUFB9
CTSV 0.725 Peptidase   4.41E-02 4.01E-01 CTSV,NPY
NFAT (complex)  Complex   4.41E-02 4.01E-01 CFLAR,SLC1A2
Angiotensin II receptor type 1  Group   4.41E-02 4.01E-01 GLP1R,NPY
CPT1C -0.322 Enzyme   4.41E-02 4.01E-01 NPY,PPARGC1A
DYRK1B 0.191 Kinase   4.41E-02 4.01E-01 CCND3,CP
KISS1 -0.12 Other   4.41E-02 4.01E-01 GSTP1,PPARGC1A
LIMA1 -0.153 Other   4.41E-02 4.01E-01 VCAN,VIM
ELF5  Transcription Regulator   4.41E-02 4.01E-01 ESR1,ITGB1
Pln 0.071 Other   4.41E-02 4.01E-01 ITGB1,RYR2
OGA -0.295 Enzyme  1.886 4.45E-02 4.01E-01
ACSS1,ACTN4,ALDOC,ARHGAP29,BACH1,CDKAL1,CX3CR1,DAGLB,EFNB2,FLNB,FN1,HSF2,IGF1,ITG
B5,NGEF,PRKG1,RPS6KA3,STAT2,VIM
SND1 -0.288 Enzyme   4.57E-02 4.01E-01 DHFR,QPCT,SMURF1
SPDEF -0.259 Transcription Regulator  1.408 4.59E-02 4.01E-01 CDH11,COL4A1,LAMC1,LEF1,VIM
ATF4 -0.149 Transcription Regulator  -0.908 4.66E-02 4.01E-01 GCH1,MCL1,PSEN1,PSPH,SLC1A4,SLC38A2,SLC7A11,WARS
SMARCA4 -0.047 Transcription Regulator  1.364 4.82E-02 4.01E-01
A2M,ACTN4,ADAM15,AP1S2,CP,DHFR,EDNRA,FAM167A,FLNB,FN1,GSTP1,HCN1,IGF1,ITGB1,KCNQ
3,KCNS3,KDR,LEF1,Mt1,NPFFR2,Ppfia4,TMCC3,VIM,ZNF24
ALKBH5 -0.092 Enzyme   4.90E-02 4.01E-01 ABI1,ALG11,CELSR2,MBP,NCOR1,TMBIM6
Creb  Group  0.923 4.93E-02 4.01E-01 APBA2,CFLAR,CLMN,CTSV,FLNB,Foxn3,GPR50,MCL1,NR3C1,PPARGC1A,RYR2,SLC7A11
PI3K (family)  Group  1.195 4.94E-02 4.01E-01 ATG12,CCND3,CFLAR,ESR1,ITGB1,PTGS1,SLC4A7
COL18A1 0.198 Other Inhibited -2.236 6.33E-02 4.11E-01 EFNB2,FGF2,FN1,KDR,MCL1
HTT -0.236 Transcription Regulator Inhibited -2.139 6.48E-02 4.18E-01
ALDOC,ARHGEF7,ATP5MF,ATP6V0E2,CLOCK,CNR1,COL4A1,CX3CL1,DNAJB1,ENPP2,ITGB1,KLF5,Mt
1,NGEF,NPY,PPARGC1A,PRELP,PSME1,SERPINA3,SESN1,SLC1A2
PPARGC1A 1.049 Transcription Regulator  1.924 7.80E-02 4.27E-01 AK1,ATP5MF,DLAT,GABPA,IMPA1,LAMA2,LPIN1,PPARGC1A,PTN,SERPINA3,TXN2,VCAN
NFkB (complex)  Complex Activated 2.098 1.31E-01 4.71E-01
AMPH,CFLAR,CRHR1,CX3CL1,Cyb5r3,DTX3,FN1,HIF3A,ITGB1,MCL1,NAMPT,RAB3C,SCLY,SLC11A2,
SLC1A2,TRPC6
AKT1 -0.114 Kinase Activated 2.18 1.74E-01 4.78E-01 CCND3,FN1,ITGB1,KLF15,SLC4A7
ITK -0.101 Kinase  -1.941 2.58E-01 5.34E-01 CX3CR1,MAF,SULF2,ZBTB16
mir-122  MicroRNA  1.997 3.00E-01 5.63E-01 LAMC1,VIM,VPS4A,WARS
NR1H4  Ligand-Dependent Nuclear Receptor Inhibited -2.156 3.48E-01 5.90E-01 ACSS1,NR3C1,PNPLA3,PPARGC1A,PTGS1
EIF4E 0.417 Translation Regulator Activated 2.219 3.67E-01 5.96E-01 FGF2,LSM1,LSM2,MCL1,SVIL
STAT5B 0.57 Transcription Regulator  1.982 4.05E-01 6.19E-01 ASAP1,CCND3,CFLAR,DAPK1,GSTP1,IGF1,MAF,MCL1
STAT5A -0.05 Transcription Regulator  1.964 4.10E-01 6.22E-01 CCND3,CFLAR,IGF1,LEF1,MAF,MCL1,QPCT,RORA,SERPINA3
IL15 0.049 Cytokine Activated 2.374 4.46E-01 6.50E-01 ALDOC,CCND3,CX3CR1,MCL1,PFKFB3,PFKP
P38 MAPK  Group  1.951 1.00E+00 1.00E+00 CRHR1,FN1,KLF15,PPARGC1A
PPARG -0.335 Ligand-Dependent Nuclear Receptor  1.987 1.00E+00 1.00E+00 ASAP1,DLAT,DLK1,FN1,FZD1,HR,IGF1,KLF11,MTTP,PFKFB3,PPARGC1A,VIM
IL10RA -0.275 Transmembrane Receptor  1.89 1.00E+00 1.00E+00 FN1,HTR4,Irgm1,NAMPT,PPARGC1A,SLC7A11,ST3GAL6
IL4 0.172 Cytokine Activated 2.358 1.00E+00 1.00E+00
ABCA2,ALDOC,CCND3,CFLAR,FLNB,IGF1,MERTK,NOMO1 (includes 
others),PFKP,PPARGC1A,SMC3,STAT2,TGFB3,VIM
DICER1 0.52 Enzyme  -1.982 1.00E+00 1.00E+00 GNG2,GREB1L,ITGB1,KDR,MAF,TRPC6,VIM,ZC3HAV1L
CSF2  Cytokine Activated 2.213 1.00E+00 1.00E+00 CCND3,IGF1,ITGB5,MCL1,RBBP4
HNF1A 0.114 Transcription Regulator Activated 2 1.00E+00 1.00E+00 FNTB,FUK,GLP1R,IGF1,MTTP,PFKP,SNX17
Supplemental Table 7: Upstream regulator analysis of genes altered after 4 weeks of Cort treatment. (Ingenuity Pathway Analysis, www.qiagen.com/ingenuity; Fisher’s exact test with Benjamini-Hochberg Correction).
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Upstream Regulator Expr Log Ratio Molecule Type Predicted Activation State Activation Z-Score Overlap P-value FDR Target molecules in dataset
FEV  Transcription Regulator   1.47E-06 2.76E-03
CHGB,CITED1,GABRQ,GRIA3,HTR1A,KCNJ16,NFIX,NPY,SCG2,SLC7A8,SLIT2,S
YT1,TCF7L2
APP -0.015 Other  1.067 9.66E-05 6.68E-02
ABCG2,ALDOC,AMPH,ATP1A3,ATP6V1A,EGFR,FLNA,GAP43,GHR,GNG2,GPR
6,L1CAM,MAP2K2,MBP,Mt1,NPY,PAK3,PCP4,PEA15,PRDX5,PRDX6,SCN1A,S
LIT2,TENM1,TPPP,TUBA8,TXN,VSNL1
MAPT 0.028 Other   1.07E-04 6.68E-02
ABCG2,AMPH,ATP1A3,ATP6V1A,BSN,CDKN1A,GNG2,GPR6,GSTM5,MAPK11
,MBP,PAK3,PCLO,PCP4,PEA15,PRDX5,PRDX6,TPPP,TUBA8,TXN,VSNL1
KRAS -0.144 Enzyme  -0.398 1.70E-04 7.73E-02
ALDOC,AMPH,CDKN1A,CTNND2,EEF1A1,EGFR,FSTL1,FTH1,GLUL,GSN,IGF1R,
LAMP2,MINOS1-
NBL1/NBL1,NCAM1,NRAS,PDPN,RELA,SDC4,SERPINA3,SPARC,SREBF1
NR3C1 0.235 Ligand-Dependent Nuclear Receptor  0.75 2.21E-04 7.73E-02
ARHGEF3,CD38,CDKN1A,CLK2,DAG1,DEAF1,DIABLO,DNER,ELMO2,ERN1,FK
BP5,GLUL,GRIA3,GRM1,GRM5,HTR1A,IGF1R,ITGAV,NPY,PDCD4,PDPN,PEA1
5,POGK,POMC,PTRH2,RAB11A,RELA,RGS2,RIPK2,SCG2,SEMA3C,SEMA5B,SL
C38A1,STON1,TNFAIP1,TXN
MKNK1 0.228 Kinase  -1.508 2.64E-04 7.73E-02
AP3D1,ATP1A3,FLNA,FLNB,GAP43,NCDN,NELL2,SPARC,TM9SF2,TRIM32,VS
NL1
miR-122-5p (miRNAs w/seed GGAGUGU)  Mature MicroRNA  -1.364 2.89E-04 7.73E-02 CCNG1,EEF1A1,MAPK11,NCAM1,NUMBL,RABIF,TRIB1,TTYH3
DLX1 -0.15 Transcription Regulator   5.65E-04 1.01E-01 BMPER,GAD1,GAD2
ASIP 0.01 Other   5.65E-04 1.01E-01 AGRP,HTR2C,NPY
VGF -0.153 Growth Factor   5.65E-04 1.01E-01 AGRP,CHGB,NPY
RXRB 0.013 Ligand-Dependent Nuclear Receptor   5.95E-04 1.01E-01 ALDH1A1,ATP1A3,CTSS,FLRT3,FSTL1,NPY,PMP22
BDNF 0.208 Growth Factor  0.431 7.09E-04 1.04E-01
CDKN1A,ELOVL6,GAD2,GAP43,HIVEP1,LAMP5,MBP,NECAB3,NPY,POMC,SO
RL1
PSEN1 -0.024 Peptidase  -1.056 7.22E-04 1.04E-01
AMPH,ATP1A3,ATP6V1A,C1QB,CTSS,DGKE,EGFR,GNG2,GPR6,L1CAM,LRP8,
MAP2K2,MBP,NCAM1,PAK3,PCP4,PEA15,PRDX5,PRDX6,TPPP,TUBA8,TXN,V
SNL1,WARS
HTT 0.102 Transcription Regulator  1.32 9.64E-04 1.08E-01
ALDOC,ATP1A1,ATP5MF,CORO2B,CSNK1E,DIO2,EDNRB,EEF1A1,ETNPPL,GA
D1,GAP43,GRM1,GSN,KCNAB1,KCNJ2,MAST3,MLF2,Mt1,NGEF,NPY,OXT,PC
P4,PEA15,PSMD3,RNF34,RPH3A,SERPINA3,SEZ6
NPBWR1 -0.181 G-Protein Coupled Receptor   9.74E-04 1.08E-01 NPY,POMC
mir-7  MicroRNA  -0.689 9.77E-04 1.08E-01 CDKN1A,IGF1R,RELA,SLC2A3
DGCR8 -0.144 Enzyme  1.276 9.84E-04 1.08E-01 MBP,NCAM1,PDCD4,PMP22,POU3F2,SOX10,TCF7L2
NFE2L2 -0.684 Transcription Regulator  0.101 1.22E-03 1.25E-01
ARHGEF3,ATP1A1,CHGB,ENTPD5,FKBP5,FTH1,GHR,GSTM5,L1CAM,Mt1,NFE
2L2,NGEF,PSMD3,RBBP7,RELA,SCG2,SERPINA3,SLC7A8,SREBF1,SYT1,SYT5,T
XN,VSNL1
DLX2 0.141 Transcription Regulator   1.27E-03 1.25E-01 BMPER,CDKN1A,GAD1,GAD2
MAOA -0.368 Enzyme   1.51E-03 1.41E-01 HTR1A,HTR2C,OXT
PI3K (complex)  Complex  -1.066 2.07E-03 1.70E-01
APLN,ETS1,FBLN5,FRY,GAP43,GSTM5,IGF1R,LASP1,NFE2L2,RGS2,SEMA6D,S
KIL,SREBF1
PHF21A 0.316 Enzyme   2.21E-03 1.70E-01 CHGB,SCG2,SYT1
IAPP  Other   2.21E-03 1.70E-01 LEPR,NPY,POMC
EPAS1 0.223 Transcription Regulator  -1.243 2.41E-03 1.70E-01 ALDOC,APLN,CDKN1A,CLK3,EGFR,ITGAV,L1CAM,PELP1,SREBF1,TAF9B,UGP2
SP4 0.228 Transcription Regulator   2.51E-03 1.70E-01 CDKN1A,EGFR,IGF1R,RELA
DPP10 -0.36 Peptidase   2.86E-03 1.70E-01 DPP10,KCNIP1
GNL3L -0.157 Other   2.86E-03 1.70E-01 CDKN1A,YWHAB
CHRM4 0.283 G-Protein Coupled Receptor   2.86E-03 1.70E-01 ITGAV,ITGB5
NUMBL 0.625 Other   2.86E-03 1.70E-01 CDKN1A,SPARC
CASP2 0.121 Peptidase   2.86E-03 1.70E-01 DIABLO,NCAM1
TP73 0.034 Transcription Regulator  1.039 2.91E-03 1.70E-01
CCNG1,CD83,CDKN1A,CITED1,CLMN,DAB1,FKBP1B,FXR1,HIVEP1,LIG1,MINO
S1-
NBL1/NBL1,PDPN,PMP22,RFX3,SCRG1,SERPINA3,TIMP4,TRIM32,VAMP4,Y
WHAB
DMP1  Other  0.447 2.93E-03 1.70E-01 C1QB,CORO2B,NPY,SLC6A9,SOX10
CERS2 0.107 Transcription Regulator   3.09E-03 1.70E-01 CDKN1A,CERS5,MBP
SIM1 -0.082 Transcription Regulator   3.09E-03 1.70E-01 OXT,POMC,POU3F2
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SOX10 -0.603 Transcription Regulator   3.69E-03 1.98E-01 DAG1,KCNB1,PMP22,SOX10
HDAC4 -0.126 Transcription Regulator   4.07E-03 2.10E-01 CDKN1A,ETNPPL,HDAC5,NTM,RGS2,RTN1,SCRG1,TSPAN13,TSPAN7
Angiotensin II receptor type 1  Group   4.15E-03 2.10E-01 ATP1A1,GAP43,NPY
TSC2 -0.221 Other  -0.284 4.95E-03 2.28E-01
ACSS2,ATP6V1A,B3GALT2,CDKN1A,FAM107A,GAP43,GSN,Mt1,SLC14A1,UC
P2
ESR2 0.008 Ligand-Dependent Nuclear Receptor  -0.473 5.28E-03 2.28E-01
BMP2,CDKN1A,CHST15,EGFR,EMB,GAD2,HTR1A,IGF1R,ME2,NPY,OXT,TEN
M4,TSPAN13
F Actin  Complex   5.60E-03 2.28E-01 CTSS,FLNA
FDX2 -0.462 Transporter   5.60E-03 2.28E-01 FTH1,IREB2
KCNIP1 0.556 Ion Channel   5.60E-03 2.28E-01 DPP10,KCNIP1
HTR2A -0.403 G-Protein Coupled Receptor   5.60E-03 2.28E-01 EGFR,GRM1
KCND3 -0.055 Ion Channel   5.60E-03 2.28E-01 DPP10,KCNIP1
FDXR -0.094 Enzyme   5.60E-03 2.28E-01 FTH1,IREB2
Pou3f1 0.104 Transcription Regulator   5.60E-03 2.28E-01 MBP,PMP22
CHD7 0.073 Enzyme  -1 6.09E-03 2.43E-01 APH1B,EGFR,NOTCH3,TULP3
MAFB -0.18 Transcription Regulator  1.195 6.62E-03 2.53E-01 ALCAM,CD38,FBLN5,LGMN,NUAK1,SLC7A8,TMEM119
NUMB -0.068 Other   6.86E-03 2.53E-01 CDKN1A,EGFR,Mt2
ATP7B 0.218 Transporter  -1.342 7.00E-03 2.53E-01 CCNG1,ELOVL6,Mt1,Mt2,SMC4
GHR 0.663 Transmembrane Receptor  1.067 7.00E-03 2.53E-01 CDKN1A,GHR,GHSR,NPY,RELA
ATOH1  Transcription Regulator   7.07E-03 2.53E-01 MGAT5B,PCP4,SLC17A6,SRRM4
SOX4 0.1 Transcription Regulator  -0.551 7.14E-03 2.53E-01 CSNK1E,EPG5,FAM213A,MBP,Mt1,NUAK1,PPM1F,SNX10,TENM4
DRD2 0.068 G-Protein Coupled Receptor   8.15E-03 2.68E-01 EDNRB,GAD1,KCNJ2,POMC
ERG 0.117 Transcription Regulator  -1 8.28E-03 2.68E-01
ARHGEF6,EGFL7,ETS1,FLNB,GMFB,GPATCH2L,IGF1R,PREX2,RAPGEF1,RPL27
A,SLIT2,TMEM263
PRKAA1 -0.073 Kinase  -1.066 8.51E-03 2.68E-01 CDKN1A,CHGB,FKBP5,GHR,GRIA3,IGF1R,ITGB5,RGS2,SORL1,TNS3
PTF1A 0.015 Transcription Regulator  -0.97 8.52E-03 2.68E-01 GAD1,GAD2,GRM5,LAMP5,NPY,SEZ6
DNAJC3 0.183 Other   8.53E-03 2.68E-01 GMFB,PEA15,SETD7
SLC6A4  Transporter   9.14E-03 2.68E-01 HTR1A,POMC
GHSR 0.612 G-Protein Coupled Receptor   9.14E-03 2.68E-01 AGRP,NPY
HOMER2 0.215 Other   9.14E-03 2.68E-01 GRM1,GRM5
SH2B1 -0.141 Other   9.14E-03 2.68E-01 AGRP,NPY
SUPT5H -0.314 Transcription Regulator   9.14E-03 2.68E-01 CDKN1A,TAF9B
NPY5R 0.349 G-Protein Coupled Receptor   9.14E-03 2.68E-01 NPY,POMC
CPE -0.058 Peptidase   9.34E-03 2.69E-01 CHGB,OXT,POMC,SCG2
GCK -0.158 Kinase   1.04E-02 2.84E-01 NPY,POMC,SREBF1
SYVN1 0.002 Transporter  1.32 1.04E-02 2.84E-01 ATP1A1,DAG1,DIO2,ERN1,HLA-A,IGF1R,ITGAV,L1CAM,NFE2L2,SLC2A3
Foxp1 -0.179 Transcription Regulator  0.254 1.06E-02 2.84E-01 DAB1,DNER,FBXL16,NGEF,PDPN
NEUROG1  Transcription Regulator  -0.816 1.09E-02 2.84E-01 CFH,F2RL2,MARC2,SCG2,SULF1,TSPAN7
Raf  Group   1.16E-02 2.84E-01 B4GALT6,CDKN1A,IGF1R,SEMA3C,STON1
FOXO3 0.218 Transcription Regulator Activated 2.156 1.24E-02 2.84E-01 APLN,CDKN1A,CERS5,EDNRB,FLNB,GSTM5,Mt1,Mt2,POMC,PTPRB,UCP2
Hmgb1  Transcription Regulator   1.25E-02 2.84E-01 CDKN1A,CHGB,SCG2
NPY1R -0.06 G-Protein Coupled Receptor   1.25E-02 2.84E-01 NPY,POMC,UCP2
FOXO4 0.169 Transcription Regulator   1.25E-02 2.84E-01 APLN,CDKN1A,CERS5,EDNRB,ELOVL6,FLNB,PTPRB
SKI 0.056 Transcription Regulator   1.25E-02 2.84E-01 CDKN1A,MBP,PMP22
BAG1 0.054 Other   1.25E-02 2.84E-01 CDKN1A,EGFR,FKBP5
CG  Complex Activated 2.14 1.26E-02 2.84E-01
APLN,BMP2,CDKN1A,EMB,HLA-
A,ITGAV,ITGB5,LEPR,MTPN,OXT,RGS2,RPS6KB1,S100A10,SDC4,SMURF2,TE
NM4,TIMP4,TMEM158,TSPAN13
NR3C2 0.043 Ligand-Dependent Nuclear Receptor  1.234 1.30E-02 2.84E-01 Apoc1,FKBP1B,FKBP5,GHR,HSPA9,RGS2,SEMA3C,SERPINA3
SPTAN1 -0.058 Other   1.34E-02 2.84E-01 CDKN1A,ITGAV
mir-192  MicroRNA   1.34E-02 2.84E-01 ALCAM,IGF1R
ERCC1 0.132 Enzyme   1.34E-02 2.84E-01 CDKN1A,GHR
SPTBN2 0.196 Other   1.34E-02 2.84E-01 NCAM1,NPY
MEOX2 -0.035 Transcription Regulator   1.34E-02 2.84E-01 ITGAV,ITGB5
ABCB7 0.041 Transporter   1.34E-02 2.84E-01 FTH1,TXN
MYCN -0.211 Transcription Regulator   1.47E-02 2.84E-01 CDK9,CDKN1A,EGFR,MTF2,NCAM1,RBBP7
CCKBR -0.342 G-Protein Coupled Receptor   1.49E-02 2.84E-01 APLN,GHSR,SPARC
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NCL 0.012 Other   1.49E-02 2.84E-01 CDKN1A,PDCD4,UBE4A
TOR1A -0.465 Enzyme   1.49E-02 2.84E-01 GMFB,PEA15,SETD7
HRG  Other   1.49E-02 2.84E-01 C1QB,CD83,SPARC
Calmodulin  Group  -1.342 1.52E-02 2.84E-01 ARPC5,OPCML,RPH3A,SEZ6,SYT1
ARNTL 0.288 Transcription Regulator   1.52E-02 2.84E-01 AGRP,ELOVL6,NPY,SREBF1
mir-148  MicroRNA   1.74E-02 2.84E-01 ALCAM,IGF1R,RELA
DGAT2 -0.021 Enzyme   1.84E-02 2.84E-01 SREBF1,UCP2
mir-503  MicroRNA   1.84E-02 2.84E-01 IGF1R,SMURF2
FRMD6 0.063 Other   1.84E-02 2.84E-01 BMP2,CDKN1A
DBI 0.226 Other   1.84E-02 2.84E-01 ACSS2,ELOVL6
PPM1A -0.001 Phosphatase   1.84E-02 2.84E-01 CDKN1A,ITGAV
RHOC -0.027 Enzyme   1.84E-02 2.84E-01 CDKN1A,GLUL
MAPK1 -0.012 Kinase  0.874 1.88E-02 2.84E-01
ARSB,BCL11A,CDKN1A,ENDOD1,GNG2,HDC,ITGAV,LIG1,MAST3,NUP188,PAI
P1,PARP12,POU2F2,PTPRK,RGS2,TMEM158
PKD1 -0.353 Ion Channel  0.302 1.91E-02 2.84E-01
ABCG2,ALDH1A1,AMPH,ATP1A1,CDKN1A,EGFR,F2RL2,GRAMD1A,JAKMIP1,
SETD7,SFXN3,ZNF711
CREBBP -0.037 Transcription Regulator   1.93E-02 2.84E-01
AHI1,ARHGEF3,CBL,CDKN1A,CORO2B,DGKE,GNG2,GRIA3,GRM1,IGF1R,RGS
2,SDC4,SREBF1,TAPBP,TNFAIP1,TUBA8,WFS1
SNCA -0.068 Enzyme  1.249 1.98E-02 2.84E-01
ALDH1A1,CHGB,DGKG,DPP10,EGFR,FAM107A,GSN,HSBP1,LAMP2,RPH3A,S
CG2,TENM1,WIPF3
DICER1 -0.264 Enzyme  -0.684 1.99E-02 2.84E-01
ACVR1C,AGRP,CCNG1,CDKN1A,GAD2,GHSR,GNG2,GREB1L,ITGAV,OPTN,PD
CD4,PMP22,RASGRP1,RTN1,SEMA3C,SPARC
GRHL2 0.045 Transcription Regulator   2.02E-02 2.84E-01 BMP2,NOTCH3,SEMA3C
CCNH 0.166 Transcription Regulator   2.02E-02 2.84E-01 CDKN1A,TAF9B,UCP2
SOD1 0.043 Enzyme   2.05E-02 2.84E-01
ALDOC,ATP1A1,FTH1,GSTM5,HSBP1,KCNAB1,Mt1,Mt2,NFE2L2,NPY,PCP4,P
RDX6,SLC17A6
RUVBL1 -0.109 Transcription Regulator  1 2.08E-02 2.84E-01 ETS1,NUCKS1,TRIM66,ZDBF2
APOE 0.07 Transporter Inhibited -2.213 2.09E-02 2.84E-01
ADGRB1,CSRP1,CTNND2,CTSS,FKBP5,GLUL,GRIA3,IGF1R,KCNAB1,LRP8,NELL
2,OGA,PEA15,RELA,SDC4,SERPINA3,UCP2
HIF1A 0.04 Transcription Regulator  0.68 2.27E-02 2.84E-01
ALDOC,APLN,CDKN1A,EDNRB,EGFR,ETS1,ITGAV,L1CAM,NUCKS1,PELP1,SCG
2,SDC4,SULF1,TAF9B,TRIM66,TXN,ZDBF2
FOXO1 0.208 Transcription Regulator  1.095 2.27E-02 2.84E-01
AFF3,AGRP,APLN,ATP6V0A1,CDKN1A,CERS5,DIO2,EDNRB,ELOVL6,FLNB,IGF
1R,ITGAV,LAMP2,NPY,PTPRB,SEMA6D,SREBF1
p70 S6k  Group   2.41E-02 2.84E-01 GAP43,SREBF1
PPM1D -0.046 Phosphatase   2.41E-02 2.84E-01 CDKN1A,RELA
LRPAP1 -0.029 Other   2.41E-02 2.84E-01 SERPINA3,SORL1
PDYN -0.153 Transporter   2.41E-02 2.84E-01 GRM1,GRM5
ULBP1 0.055 Transmembrane Receptor   2.41E-02 2.84E-01 CD83,HLA-A
NTRK2 0.07 Kinase   2.45E-02 2.84E-01 ABCG2,BMP2,CDKN1A,GAD1,SYT1
SREBF1 -0.575 Transcription Regulator  1.551 2.52E-02 2.84E-01
ACSS2,AK4,ALDOC,CDKN1A,CSRP1,ELOVL6,PMP22,PMPCA,SERPINA3,SORBS
3,SREBF1,UCP2
TCF7L2 -0.64 Transcription Regulator  -0.5 2.52E-02 2.84E-01
CDKN1A,CSRP1,EGFR,ENTPD5,FA2H,FTH1,GLUL,GSN,MBP,MOBP,NKAIN2,PE
X5L,RCBTB1,SDC2,SORBS3,SOX10,TPPP
CBX5 0.171 Transcription Regulator  -0.378 2.54E-02 2.84E-01 BCL11A,CDKN1A,PCP4,SERPINA3,SLC2A3,SLC7A8,TIMP4,TSPAN13
PRKCE -0.194 Kinase  0.197 2.63E-02 2.84E-01 CDKN1A,EGFR,PDCD4,POMC,RGS2
FGFR1 -0.206 Kinase  1.474 2.64E-02 2.84E-01 CDKN1A,EEF1A1,MBP,PDCD4,POU2F2,SPARC
GJA1 -0.08 Transporter   2.65E-02 2.84E-01 BMP2,CDKN1A,MBP
HDL-cholesterol  Complex Inhibited -2 2.75E-02 2.84E-01 GPT2,MBD5,RASGRP1,TRIM66
HSF2 -0.006 Transcription Regulator   2.75E-02 2.84E-01 HSBP1,PSMD3,STAG2,TXN
ERK1/2  Group  -0.307 2.79E-02 2.84E-01
APH1B,APLN,CDKN1A,FKBP5,GAD1,HLA-
A,IGF1R,LEPR,MAP2K2,POMC,SKIL,TAPBP
mir-8  MicroRNA  -1.018 2.80E-02 2.84E-01 CDKN1A,ETS1,PPM1F,RPS6KB1,YWHAB,ZEB2
MECP2 -0.125 Transcription Regulator  -0.085 2.92E-02 2.84E-01 EHMT2,FKBP5,GAD1,HRASLS,MBP,SLC2A3,YWHAB
ASCL1 0.122 Transcription Regulator  0.447 2.97E-02 2.84E-01 GAD1,GRM5,LAMP5,NPY,NUMBL,SEZ6
IPMK -0.019 Kinase   3.00E-02 2.84E-01 CSRP1,FLNA,PMP22
NRF1 0.322 Transcription Regulator  -0.277 3.00E-02 2.84E-01 ATP1A1,FTH1,Mt1,VSNL1
NEUROD1 -0.004 Transcription Regulator   3.00E-02 2.84E-01 MGAT5B,NCAM1,SLIT2
DLX5 -0.283 Transcription Regulator   3.00E-02 2.84E-01 BMPER,CITED1,GAD2
Cdc42 -0.096 Enzyme  1 3.00E-02 2.84E-01 ATP6V1A,CTSS,FLNA,LAMP2
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HOXA11-AS  Other   3.03E-02 2.84E-01 CDKN1A,ZEB2
Actin  Group   3.03E-02 2.84E-01 FLNA,KCNB1
TNFRSF8 0.251 Transmembrane Receptor   3.03E-02 2.84E-01 CDKN1A,PDPN
RLIM 0.01 Enzyme   3.03E-02 2.84E-01 CDKN1A,SKIL
LCOR -0.254 Transcription Regulator   3.03E-02 2.84E-01 CDKN1A,FKBP5
NR1I3 -0.007 Ligand-Dependent Nuclear Receptor  1.029 3.07E-02 2.84E-01 ALDH1A1,CDKN1A,GSTM5,Mt1,RPA2,SHOC2,SREBF1
WDR82 0.005 Other   3.12E-02 2.84E-01 CDKN1A
myosin-light-chain kinase  Group   3.12E-02 2.84E-01 EGFR
TFIIH  Complex   3.12E-02 2.84E-01 CDKN1A
Ces1b/Ces1c  Enzyme   3.12E-02 2.84E-01 GHR
LINC00475  Other   3.12E-02 2.84E-01 CDKN1A
IGF2BP2  Translation Regulator   3.12E-02 2.84E-01 ELOVL6
EGFLAM -0.094 Other   3.12E-02 2.84E-01 DAG1
OPHN1 -0.001 Other   3.12E-02 2.84E-01 GRM1
TTC7A 0.219 Other   3.12E-02 2.84E-01 EGFR
ARMC10 0.222 Other   3.12E-02 2.84E-01 CDKN1A
SV2B 0.09 Transporter   3.12E-02 2.84E-01 SYT1
FKBPL -0.22 Other   3.12E-02 2.84E-01 CDKN1A
ZBTB7C -0.293 Transcription Regulator   3.12E-02 2.84E-01 CDKN1A
ZGPAT 0.197 Transcription Regulator   3.12E-02 2.84E-01 EGFR
March6 -0.192 Enzyme   3.12E-02 2.84E-01 DIO2
NLGN2 0.021 Enzyme   3.12E-02 2.84E-01 GAD2
TBC1D16 -0.299 Other   3.12E-02 2.84E-01 EGFR
B3GALT1 0.387 Enzyme   3.12E-02 2.84E-01 B3GALT5
CHMP6 0.316 Other   3.12E-02 2.84E-01 EGFR
CXXC1 -0.146 Transcription Regulator   3.12E-02 2.84E-01 CDKN1A
PCLAF  Other   3.12E-02 2.84E-01 CDKN1A
OSBP -0.048 Transporter   3.12E-02 2.84E-01 SREBF1
WNT16 0.035 Other   3.12E-02 2.84E-01 CDKN1A
SV2A -0.094 Transporter   3.12E-02 2.84E-01 SYT1
Raet1a  Other   3.12E-02 2.84E-01 HLA-A
FILIP1 0.141 Other   3.12E-02 2.84E-01 FLNA
MYO1C 0.164 Enzyme   3.12E-02 2.84E-01 GSN
FBLIM1  Other   3.12E-02 2.84E-01 EGFR
Raet1b  Other   3.12E-02 2.84E-01 HLA-A
NECTIN3  Other   3.12E-02 2.84E-01 Pvr
PACSIN2 0.17 Transporter   3.12E-02 2.84E-01 EGFR
ADAMTS3 -0.244 Peptidase   3.12E-02 2.84E-01 DAB1
CABLES1 -0.387 Other   3.12E-02 2.84E-01 CDKN1A
ARFGEF2 -0.059 Other   3.12E-02 2.84E-01 FLNA
LINC00963  Other   3.12E-02 2.84E-01 EGFR
Rcan1  Other   3.12E-02 2.84E-01 FLNA
miR-520g-3p (and other miRNAs w/seed CAAAGUG)  Mature MicroRNA   3.12E-02 2.84E-01 ABCG2
mir-329  MicroRNA   3.12E-02 2.84E-01 GAD2
miR-542-5p (miRNAs w/seed CGGGGAU)  Mature MicroRNA   3.12E-02 2.84E-01 EGFR
mir-500  MicroRNA   3.12E-02 2.84E-01 GAD1
mir-493  MicroRNA   3.12E-02 2.84E-01 IGF1R
H60a  Other   3.12E-02 2.84E-01 HLA-A
SALL2 0.013 Transcription Regulator   3.12E-02 2.84E-01 CDKN1A
LGMN -0.404 Peptidase   3.12E-02 2.84E-01 EGFR
ZBTB5 0.049 Transcription Regulator   3.12E-02 2.84E-01 CDKN1A
ELAVL4 -0.096 Translation Regulator   3.12E-02 2.84E-01 GAP43
DHX8 -0.485 Enzyme   3.12E-02 2.84E-01 CDKN1A
KAT7 -0.222 Enzyme   3.12E-02 2.84E-01 CDKN1A
Raet1d/Raet1e  Other   3.12E-02 2.84E-01 HLA-A
KCNA1 0.314 Ion Channel   3.12E-02 2.84E-01 KCNB1
DNASE1L3 -0.036 Enzyme   3.12E-02 2.84E-01 CDKN1A
CCNI 0.082 Other   3.12E-02 2.84E-01 CDKN1A
LAMP1 0.093 Other   3.12E-02 2.84E-01 LAMP2
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ARSA -0.137 Enzyme   3.12E-02 2.84E-01 MBP
CCNT2 -0.28 Transcription Regulator   3.12E-02 2.84E-01 CDK9
SLC1A5 0.015 Transporter   3.12E-02 2.84E-01 SLC38A1
CHL1 -0.218 Other   3.12E-02 2.84E-01 NCAM1
LARGE1  Enzyme   3.12E-02 2.84E-01 DAG1
SH3GL1 -0.007 Other   3.12E-02 2.84E-01 GRM1
VPS25 0.008 Other   3.12E-02 2.84E-01 EGFR
TBX19 0.2 Transcription Regulator   3.12E-02 2.84E-01 POMC
DLGAP3 -0.281 Other   3.12E-02 2.84E-01 GRM5
ERCC6 0.353 Transcription Regulator   3.12E-02 2.84E-01 MBP
CLCNKB  Ion Channel   3.12E-02 2.84E-01 PNPLA6
ONECUT2 0.142 Transcription Regulator   3.12E-02 2.84E-01 SYTL4
DIDO1 -0.161 Other   3.12E-02 2.84E-01 ITGAV
ISCU -0.162 Other   3.12E-02 2.84E-01 FTH1
LEPR 0.703 Transmembrane Receptor  -0.615 3.23E-02 2.92E-01 AGRP,GAP43,LEPR,LGMN,MBP,NPY,POMC,SREBF1,TCF7L2,UCP2
mir-146  MicroRNA   3.37E-02 3.02E-01 EGFR,MBP,RELA
CLU -0.151 Other   3.37E-02 3.02E-01 CDKN1A,RELA,SREBF1
DYSF -0.135 Other   3.50E-02 3.12E-01 C1QB,CD83,CTSS,EHMT2,HLA-A,SERPINA3
HNF4A  Transcription Regulator  -0.531 3.53E-02 3.12E-01
ACSS2,ADGRB1,ALCAM,CDKN1A,CUL5,FTH1,GSN,HLA-
A,IGF1R,LEPR,Mt1,Mt2,N4BP1,NFE2L2,SERPINA3,SREBF1,SYBU,TCF7L2,TEN
M4,TXN,UCP2,VSNL1
TRIM24 -0.071 Transcription Regulator  -1.342 3.54E-02 3.12E-01 CSRP1,EMB,FLRT3,GLUL,PARP12,PRPS2,SAMD9L
PML 0.28 Transcription Regulator  1 3.70E-02 3.12E-01 CDKN1A,EGFR,NFE2L2,SREBF1,TXN,UCP2
AFAP1-AS1  Other   3.71E-02 3.12E-01 LASP1,RAB11A
Collagen Alpha1  Group   3.71E-02 3.12E-01 CDKN1A,EGFR
ETV1 -0.001 Transcription Regulator   3.71E-02 3.12E-01 ITGAV,POMC
RB1CC1 -0.11 Other   3.71E-02 3.12E-01 CDKN1A,SKIL
MGAT3 -0.177 Enzyme   3.71E-02 3.12E-01 DAG1,NOTCH3
USP8 -0.124 Peptidase   3.71E-02 3.12E-01 EGFR,POMC
LMX1A  Transcription Regulator   3.71E-02 3.12E-01 CORIN,SLIT2
RELN -0.366 Peptidase   3.71E-02 3.12E-01 DAB1,GAD1
Sik1 -0.001 Kinase   3.71E-02 3.12E-01 DIO2,SREBF1
CAMKK2 -0.584 Kinase   3.71E-02 3.12E-01 CDKN1A,KCNB1
CCR1 -0.012 G-Protein Coupled Receptor   3.77E-02 3.12E-01 CTSS,ITGAV,SPARC
Cdkn1c -0.373 Other   3.77E-02 3.12E-01 CDKN1A,PMP22,SOX10
Fus -0.203 Transcription Regulator   3.77E-02 3.12E-01 AHI1,Fam193b,KCNIP1
TCF  Group   3.90E-02 3.19E-01 ALDH1A1,CTNND2,DIO2,GAD1,SEMA3C,SERPINA3
VCAN 0.01 Other  -0.956 3.91E-02 3.19E-01 CDH13,CDKN1A,DAG1,FBLN5,NOTCH3,PRDX5,RGS2,TCF7L2
XBP1 -0.175 Transcription Regulator  1.015 3.91E-02 3.19E-01 APBB2,COPZ1,ETS1,FKBP1B,RELA,SPARC,SRPRA,SSR2,TXN,VAMP4,WFS1
HIC1 0.035 Transcription Regulator  -1.387 3.91E-02 3.19E-01 LRP8,SFXN3,TMEM47,TMEM62,TNS3
HR 0.343 Transcription Regulator  0 4.14E-02 3.34E-01 CTNND2,KCNIP1,PREX2,UBR2
NR1I2  Ligand-Dependent Nuclear Receptor  0.6 4.14E-02 3.34E-01 ALDH1A1,Apoc1,CDKN1A,ELOVL6,ENTPD5,GLUL,GSTM5,RELA,SREBF1
SREBF2 -0.071 Transcription Regulator  1.293 4.41E-02 3.47E-01 ACSS2,ALDOC,CDKN1A,ELOVL6,SREBF1
SNHG20  Other   4.44E-02 3.47E-01 CDKN1A,ZEB2
LHX1 -0.036 Transcription Regulator  0.478 4.44E-02 3.47E-01 DAB1,EMB,FAM213A,GAD1,PCP4,PDPN,SEMA6D
BTRC 0.069 Enzyme   4.44E-02 3.47E-01 GLUL,RELA
LOX 0.022 Enzyme   4.44E-02 3.47E-01 IGF1R,RELA
HBA1/HBA2  Transporter  1 4.45E-02 3.47E-01 ATP5MF,Mt1,UCP2,VHL
SOX17 0.007 Transcription Regulator   4.63E-02 3.47E-01 AP2M1,SPARC,VIT
TXN 0.395 Enzyme   4.63E-02 3.47E-01 CD38,RELA,TXN
PRKAA2 0.121 Kinase  -0.946 4.83E-02 3.47E-01 CDKN1A,CHGB,ERN1,GRIA3,SORL1,SREBF1,TNS3
KDM5A 0.073 Transcription Regulator  -1.414 4.94E-02 3.47E-01 ATP1A1,COX14,GPT2,HSBP1,MYL6B,NDUFB10,REEP1,RPS6KB1
ALKBH5 0.154 Enzyme   4.99E-02 3.47E-01 GSTM5,MBP,RGS2,SLC7A8,STAG2,STON1
REST -0.453 Transcription Regulator   4.99E-02 3.47E-01 CHGB,GAD1,GAP43,GRM1,SCG2,SRRM4
SHC1 0.051 Other  1.981 5.12E-02 3.47E-01 CDKN1A,FTH1,SDC4,TXN
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NUPR1 -0.128 Transcription Regulator  1.964 1.10E-01 3.96E-01
ALDOC,ATP6V0A1,C6orf203,ETS1,GABBR1,IGF1R,LRP8,NRSN2,NUCKS1,PEA
15,PLEKHM3,PMP22,PMPCA,PRR12,RCL1,RFTN2,RTN4IP1,TMEM158,TNS3,
TRIB1,ZNF483
RHO 0.041 G-Protein Coupled Receptor Inhibited -2 1.17E-01 3.96E-01 CTSS,KCNB1,Mt1,NCAM1
JUN 0.111 Transcription Regulator Inhibited -2.217 1.61E-01 4.16E-01 CDKN1A,DIO2,FTH1,GAP43,IGF1R,ITGAV,MBP,PEA15,TCF7L2,ZEB2,ZNF385A
CLOCK 0.204 Transcription Regulator Inhibited -2.236 1.64E-01 4.16E-01
AK4,ARHGEF28,EGFR,ELOVL6,FAM107A,FKBP5,MTPN,TAF9B,TIMP4,TNFAIP
1,ZDBF2
GLI1 -0.236 Transcription Regulator Activated 2.2 2.11E-01 4.63E-01 ABCG2,ARPC5,CDKN1A,DIO2,GRIA3,MAPK11
TP53 -0.086 Transcription Regulator Activated 2.139 2.18E-01 4.68E-01
ABCG2,ABHD4,ACOT11,ACSL6,ACSS2,ADGRB1,AK4,APBB2,ASTN2,ATL3,CCN
G1,CDKN1A,COQ2,CSRP1,DLGAP1,EEF1A1,EGFR,FKBP1B,FKBP5,FSTL1,FTH1,
GFM1,GLUL,GSN,GSTM5,HRASLS,IGF1R,IPO9,IREB2,ITGAV,ITGB5,KCNB1,KC
NJ2,LASP1,LIMK2,MAP2K2,ME2,MLF2,Mt2,ORAI2,PAK3,PCBP4,PPM1F,PRD
X6,PSMD3,RBBP7,RPS6KB1,SEMA3C,SERPINA3,SMC4,SMURF2,SREBF1,TCF7
L2,VAMP4,ZEB2
VEGFA -0.106 Growth Factor Activated 2.216 3.02E-01 5.26E-01 CD83,CTSS,DIABLO,ETS1,ITGAV
SPARC 0.282 Other Inhibited -2 3.95E-01 5.84E-01 APH1B,DAB1,LRP8,NPY
CLDN7 -0.061 Other  -1.987 5.25E-01 6.67E-01 LYSMD2,MRPL36,TSPAN12,WIPI1
CD3  Complex Inhibited -2 1.00E+00 1.00E+00 CBL,ETS1,GRM1,ORAI2,PHB2
Jnk  Group  -1.91 1.00E+00 1.00E+00 AGRP,APLN,CD83,ETS1
PRKCD -0.131 Kinase  1.99 1.00E+00 1.00E+00 CDKN1A,MRPS11,PDCD4,SETBP1
TGM2 0.076 Enzyme  1.982 1.00E+00 1.00E+00 ACSS2,IGF1R,SAMD9L,VHL
IFNG  Cytokine  1.895 1.00E+00 1.00E+00
ATP1A1,C1QB,CD38,CDKN1A,CTSS,DIABLO,EDNRB,FAM107A,FTH1,GLUL,G
NG2,HLAA,ITGAV,MAP2K2,NOTCH3,POMC,RIPK2,SDC4,SEMA4A,SREBF1,TA
PBP,TCF7L2,TIMP4,TRPC4
Supplemental Table 8: Upstream regulator analysis of genes altered after 2 days of Cort treatment. (Ingenuity Pathway Analysis, www.qiagen.com/ingenuity; Fisher’s exact test with Benjamini-Hochberg Correction).
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Wray et al. Supplemental Figure 1
BA
Supplemental Figure 1: Principal component analysis. Outlier samples were detected based on 
global transcriptomic profiles in principal component analysis (PCA) plots for (a) 2 day (n=5) and (b) 4 
week datasets (n=5). Two vehicle and one Cort outlier were identified in each group (marked with 
stars; 2 day: C07, C08, C09; 4 week: C01, C05, C06). Vehicle samples are represented in red, Cort 
samples in cyan. 
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Wray et al. Supplemental Figure 2
Supplemental Figure 2: The effects of exogenous Cort delivery on levels of circulating corticosterone. 
(a) Circulating corticosterone concentrations at the peak (n = 8-10/group; t16 = 9.84, P <0.0001) and (b) 
nadir of the endogenous rhythm (n = 10/group; t18 = 8.065, P <0.0001). White bars, vehicle (Veh); Black 
bars, 75µg/ml corticosterone (Cort) treated. ZT1, 7am; ZT13, 7pm. ***P<0.001. (a, b) Unpaired student’s 
t-test. 
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Supplemental Figure 3:  The phenotypic effects of exogenous Cort treatment over 4 weeks. (a) Daily food 
intake (n = 10/group; time: F8, 144 = 3.01, P = 0.0037; interaction: F8, 144 = 1.422, P = 0.1921; treatment: F1, 18 = 
26.03, P <0.0001) and (b) cumulative food intake across the treatment period (n=10/group; time: F8, 144 = 1572, 
P <0.0001; interaction: F8, 144 = 14.84, P <0.0001; treatment: F1, 18 = 9.297, P = 0.0069). (c) Body weight across 
the treatment period (n = 10/group; time: F8, 144 = 118.3, P <0.0001; interaction: F8, 144 = 41.37, P <0.0001; 
treatment: F1, 18 = 31.5, P <0.0001). (d) Epididymal, subcutaneous and mesenteric adipose tissue weights at the 
time of cull (n = 9-10/group; Epi, t18 = 5.942, P <0.0001; Subcut, t17 = 11.36, P <0.0001; Mes, t18 = 3.713, P = 
0.0016). (e) Fasted blood glucose (n = 9-10/group; t17 = 0.04999, P = 0.9607), (f) insulin (n=10/group; t18 = 3.623, 
P = 0.0019), and (g) HOMA-IR after 29 days of Cort treatment (n = 10/group; t18 = 3.364, P = 0.0035). Epi, 
epididymal; Subcut, subcutaneous; Mes, mesenteric. White bars, vehicle (Veh); Black bars, 75µg/ml 
corticosterone (Cort) treated. *P<0.05, **P<0.01, ***P<0.001. (a-c) Two-way ANOVA with Sidak’s post-hoc 
comparison, (d-g) unpaired student’s t-test. 
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Wray et al. Supplemental Figure 4
Supplemental Figure 4:  The phenotypic effects of exogenous Cort treatment over 2 days. (a) Total food 
intake (n=9-10/group; P = 0.0041) and (b) body weight after the 2 day treatment period (n = 9-10/group; t17
= 0.0081, P = 0.9936). (c) Individual adipose tissue bed and muscle weights at the time of cull (n = 9-
10/group; Epi: t17 = 1.726, P = 0.1024; Subcut: t18 = 1.746, P = 0.0979; Mes: t17 = 0.5725, P = 0.5745; BAT: t16
= 3.985, P = 0.0011; Muscle: t16 = 1.991, P = 0.0639). (d) Circulating blood glucose (n = 10/group; t18 = 2.109, 
P = 0.0492) and (e) insulin after 2 days of treatment (n = 9/group; t16 = 2.202, P = 0.0427). Epi, epididymal; 
Subcut, subcutaneous; Mes, mesenteric. White bars, vehicle (Veh); Black bars, 75µg/ml corticosterone (Cort) 
treated. *P<0.05, **P<0.01, ***P<0.001. (a) Mann-Whitney test, (b-e) Unpaired student’s t-test. 
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Wray et al. Supplemental Figure 5
Supplemental Figure 5: Validation of 2 day RNA-seq results. Validation of 2 Day RNA-seq results by qRT-
PCR in laser capture microdissected ARC tissue from 2 day Cort treated mice. . Each gene is expressed as fold 
change relative to the vehicle control, represented by the horizontal dotted line (n = 6-7/group). Red bars = 
genes up regulated in RNA-seq; blue bars = genes down regulated in RNA-seq (n = 6-7/group). *P<0.05, 
**P<0.01, ***P<0.001. Unpaired student’s t-test.
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Wray et al. Supplemental Figure 6
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Supplemental Figure 6:  Dio2 expression in whole hypothalami following 3 week chronic Cort treatment. 
Dio2 mRNA expression is increased in whole hypothalami after 3 weeks of oral Cort treatment (n = 8/group; 
P = 0.0002). White bar, vehicle (Veh), black bar, 75µg/ml corticosterone (Cort) treated. ***P<0.001. Mann-
Whitney test.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Hex Amplitude Hex Amplitude Hex Amplitude Hex Amplitude
FA
M
 
Am
pl
itu
de
AAV-gRNA (Rep 2) AAV-gRNA (Rep 4)AAV-gRNA (Rep 1) AAV-gRNA (Rep 3)
Hex Amplitude Hex Amplitude Hex Amplitude
Hex Amplitude Hex Amplitude Hex Amplitude
FA
M
 
Am
pl
itu
de
FA
M
 
Am
pl
itu
de
AAV-null (Rep 2)AAV-null (Rep 1) AAV-null (Rep 3)
AAV-null (Rep 5)AAV-null (Rep 4) AAV-null (Rep 6)
FA
M
 
Am
pl
itu
de
Hex Amplitude Hex Amplitude
NTC (No Pre-Amp) NTC (Pre-Amp)
Non-template 
controls (NTCs)
Individual 
CRISPR treated
Individual 
Control treated
Wray et al. Supplemental Figure 7
Supplemental Figure 7: Individual ddPCR plots. DNA was extracted from the laser capture microdissected
mediobasal hypothalamic tissue of AAV-null and AAV-gRNA injected mice. All plots represent individual replicates 
from each animal. Reference probe, FAM; InDel+ probe, Hex. Pink bars indicate manually set thresholds. Orange 
dots, wild type DNA; blue dots, DNA containing InDels; grey dots; empty droplets.
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Wray et al. Supplemental Figure 8
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Supplemental Figure 8:  SaCas9 expression in MBH micropunches. Ct values of SaCas9 mRNA measured in 
micropunches taken from the mediobasal hypothalamus of AAV-injected mice. Dashed line indicates the 
cutoff Ct vale of 33. All samples above this threshold were determined to be “missed” injections and were 
excluded from all subsequent analysis. Ct, cycle threshold (n = 9-14/group).
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Highlights 
 
• RNA-seq reveals multiple genes changed by Cort in the arcuate nucleus 
• Corticosterone increases Dio2 expression in the mediobasal hypothalamus 
• Dio2 increase associated with greater food intake after 2 day Cort 
• CRISPR-Cas9 knockdown of Dio2 attenuates the Cort-induced increase in Agrp 
• Elevated Dio2 does not drive the GC-induced adverse metabolic effects. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Declarations of interest: 
None declared. 
 
